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Adolescent girls and young women (AGYW) in sub-Saharan Africa represent a key 
population at risk for acquiring HIV infection. Oral antiretroviral pre-exposure prophylaxis, or 
PrEP, is an efficacious biomedical HIV prevention strategy that holds enormous potential to 
reduce HIV acquisition in key populations if taken consistently. Research is needed to identify 
barriers and facilitators to PrEP adherence among AGYW to inform implementation efforts. The 
aims of this dissertation were to examine how disclosure of PrEP use and intimate partner 
violence (IPV) affect adherence to daily oral PrEP among AGYW in southern Africa.  
We used data from two prospective cohort studies evaluating PrEP uptake and 
adherence among sexually-active HIV-uninfected women aged 16-25 years. Participants who 
initiated once daily oral PrEP were included in analyses. We first conducted descriptive analysis 
of PrEP use disclosure and IPV exposure variables. Participants self-reported disclosure of their 
PrEP use during follow-up separately for parents, partners, and peers. IPV included any self-
reported physical, emotional, sexual, or psychological partner violence. Then, for both aims, we 
estimated the relative prevalence of high PrEP adherence at months 3 and 6, defined as TFV-
DP ≥700 fmol/punch at a given visit, using univariate and multivariable (adjusted) modified 
Poisson or log-binomial regression. Effects were estimated in the full study population and 
within younger and older AGYW age group strata (dichotomized at the sample median).  
We did not observe a strong effect of disclosure or IPV on adherence overall; however, 
the effect of disclosure to a parent and IPV were significantly modified by age (α=.15). For the 
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parent disclosure-adherence relationship, there was evidence of effect modification by age at 
month 6 (p=.062): among younger AGYW (≤18 years), those who disclosed to a parent were 6.8 
times as likely to have high adherence at month 6 than those who did not (95% CI 1.02, 45.56); 
among older AGYW (>18 years), there was no significant effect of disclosure to a parent 
(aPR=0.69, 95% CI 0.17, 2.90). For the IPV-adherence relationship, there was evidence of 
effect modification by age at month 3 (p<.001): among younger AGYW (<21 years), those who 
reported IPV were less than half as likely to have high PrEP adherence (aPR=0.43, 95% CI 
0.22, 0.86); among older AGYW (≥21 years), those who reported IPV were more than twice as 
likely to have high PrEP adherence (aPR=2.21, 95% CI 1.34, 3.66). There was also evidence of 
effect modification by age for the IPV-adherence relationship at month 6 (p=.128), and effect 
estimates within each age stratum were consistent in direction with month-3 results. 
Findings from our investigation of disclosure and PrEP adherence suggest that parents 
may play an important role in facilitating PrEP use among younger AGYW, and more work is 
needed to develop strategies for engaging parents in their child’s PrEP use. Further, adherence 
support programs for AGYW should find ways that peers and partners can help motivate 
effective PrEP use. Findings from our investigation of IPV and PrEP adherence suggest that 
adherence programs may be especially necessary to support younger AGYW who have 
experienced violence from a partner previously or are currently in a violent partnership. Further, 
insight into the indirect effects of IPV among older AGYW may inform efforts aimed at optimizing 
adherence among younger AGYW. Alternative PrEP formulations may provide benefits for 
AGYW who have trouble adhering to a daily oral PrEP regimen. Lastly, findings from both aims 
suggest that the impact of social and behavioral factors on PrEP adherence is likely to vary 
between younger and older AGYW. Future research should consider the transitional nature of 
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CHAPTER I: SPECIFIC AIMS 
 
Adolescents and young adults account for over one-third of all new global infections of 
HIV, representing a key population for prevention efforts. In sub-Saharan Africa (SSA), where 
the vast majority of infections occur, adolescent girls and young women (AGYW) 15-24 years 
alone contribute nearly 25% of all new HIV infections in the region and are more than twice as 
likely to become infected with HIV than their male counterparts (1). Oral antiretroviral pre-
exposure prophylaxis, or PrEP, is a biomedical HIV prevention strategy that holds enormous 
potential to substantially reduce HIV acquisition in key populations globally. While research has 
shown a reduction in HIV acquisition greater than 90% with oral PrEP when adherence is high 
(2–4), in FEM-PrEP and VOICE trials, both of which were conducted among African women, 
adherence was exceptionally low compromising PrEP’s efficacy (5,6). Further, the few 
demonstration projects inclusive of adolescents under 18 years of age have shown us that 
adherence to daily PrEP may be an even greater challenge for younger populations (7,8).  
Recent recommendations for improving PrEP adherence suggest that tailored PrEP 
delivery programs are necessary to meet the needs of African AGYW (9). Research is needed, 
however, to identify specific considerations relevant to the implementation of PrEP among 
AGYW in generalized epidemic settings. In SSA, a lack of social support and intimate partner 
violence (IPV), both of which are common among young women in this context, have been 
linked to poor adherence to antiretroviral therapy (ART) (10,11). Further, studies have described 
the importance of social support and disclosure of PrEP use for adherence in PrEP and 
microbicide trials, as well as the role of IPV as a barrier to both disclosure and adherence (12–
16). Given the concerns surrounding adherence, the objective of this study was to examine the 
effect of PrEP use disclosure and IPV on PrEP adherence among AGYW in southern Africa. 
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This study utilized longitudinal cohort data from two prospective PrEP implementation 
studies. The first aim utilized data from the 3Ps for prevention study (3P), which enrolled 200 
AGYW in Cape Town, South Africa (17). The second aim utilized data from the HIV Prevention 
Trials Network 082/HERS study (HPTN 082), which enrolled 451 AGYW across three sites in 
South Africa and Zimbabwe (18). For both aims, tenofovir-diphosphate (TFV-DP) concentrations 
in dried blood spots (DBS) were used as a biologic assessment of PrEP adherence.  
 
The specific aims of this study were to:  
AIM 1: 
 
Examine the relationship between PrEP use disclosure to various social groups 
and PrEP adherence among AGYW in the 3Ps for Prevention study 
AIM 2: Examine the relationship between history of IPV and PrEP adherence among 
AGYW in the HIV Prevention Trials Network 082 study 
 
Oral PrEP offers an exciting opportunity for AGYW to protect themselves from HIV given 
they are able use it effectively. However, the relative paucity of adolescent-focused PrEP 
studies when compared to adult studies poses a significant challenge for understanding whether 
PrEP would be acceptable to young people, how the developmental stage of adolescence might 
impact adherence (and thus efficacy), and how PrEP should be integrated into effective 
combination prevention packages for this high-risk group. This research can advance HIV 
prevention science by providing insight into the social and behavioral dynamics that may 











CHAPTER II: BACKGROUND 
 
REVIEW OF THE LITERATURE  
This study is particularly relevant as PrEP rollout is expanding to include adolescents 
globally. AGYW in SSA represent a key population at risk for acquiring HIV infection with unique 
needs with respect to biomedical, behavioral, and structural interventions to prevent HIV (19). 
Adolescents and young people are at a critical age in their developmental trajectory, often 
facing milestones such as sexual debut and increased engagement in sexual partnerships. HIV 
prevention options, including oral PrEP, should be explored in conjunction with sexual decision 
making. Adherence to PrEP, however, has been found to be challenging for adolescents and 
young people, which can reduce the effectiveness of PrEP. This research utilizes behavioral 









HIV in adolescent girls and young women 
Adolescents and young adults aged 15-24 years account for over one-third of all new 
global infections of HIV; in SSA where the vast majority of infections occur, AGYW alone 
contribute nearly 25% of all new HIV infections in the region (1). Further, in South Africa young, 
women account for four times the number of new infections than young men (see Figure 2.1) 
and acquire HIV around 5-7 years earlier, often synonymously with sexual debut (20,21). 
Women are particularly vulnerable to HIV during adolescence and young adulthood due to a 
combination of biological, behavioral, and structural factors (22). Prevention interventions 
implemented among AGYW require careful attention to developmental issues, including social 
and sexual relationships, as well as broader contextual issues, such as poverty, discrimination, 
gender and power inequities, and stigma (19). Behavioral and structural interventions alone 
have not been successful in reducing risk in this population. 
 
PrEP and concerns surrounding adherence  
PrEP has been found in clinical trials to be an efficacious biomedical HIV prevention 
strategy that holds enormous potential to reduce HIV acquisition in key populations globally. 
Although different modalities (e.g., oral, topical, injectable, insertable) and dosing regimens 
(e.g., daily, intermittent, event-driven) of PrEP administration are currently under consideration, 
efficacy of daily oral PrEP has the most empirical support (23–25). Evolving data from 
randomized trials and demonstration projects among adult men have shown a reduction in HIV 
acquisition of greater than 90% with oral PrEP when adherence is high, with the majority of 
breakthrough infections occurring among those who discontinue PrEP (2–4). Among young 
African women specifically, PrEP demonstration studies have shown promise in regard to 
adherence. Data from the TDF2 open-label PrEP study in Botswana found that 87% of women 
enrolled in the study had detectable tenofovir (TFV) in plasma over time (26). Further, in the 
Partners PrEP trial, an open-label study of PrEP and ART delivery among heterosexual HIV 
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serodiscordant couples in Kenya and Uganda, adherence was estimated to be 92% among all 
participants, with efficacy ranging from 66-71% in women (27). 
In contrast to these promising findings, in FEM-PrEP and VOICE trials, where the safety 
and effectiveness of daily oral PrEP was assessed in African women, overall adherence was 
exceptionally low, with TFV detected in approximately 30% of plasma samples, compromising 
any PrEP efficacy (5,6). It is also important to note that these trials all included women 18 years 
of age and older. Adolescents under 18 years of age still remain inadequately represented in 
biomedical HIV prevention research, posing a significant challenge for integrating PrEP into 
prevention programs for this group and identifying gaps in adherence (28). The first exclusively 
adolescent focused (15-19 years), open-label oral PrEP study in SSA, the Pluspills study, 
recently found that only 17% of participants had achieved levels of adherence associated with 
high PrEP efficacy among adult men at week 24 and 16% at week 48 (8). Randomized, 
placebo-controlled PrEP trials have demonstrated that efficacy to daily oral PrEP is strongly 
related to adherence (27,29–31). Further, pharmaco-kinetic studies examining concentrations of 
TFV in vaginal and rectal tissue have indicated that women are able to miss fewer doses 
compared to men for PrEP to still be effective, making proper adherence critical (32).  
The highly variable and often suboptimal adherence rates observed among AGYW in 
PrEP trials are consistent with rates of adherence to other preventative health interventions, 
including oral contraception, and rates of adherence to ART observed among adolescents and 
young people living with HIV (33–36). AGYW may have greater difficulty with adherence than 
older women and other populations due in part to social, behavioral, and psychological factors, 
which have been identified as predictors of non-adherence in studies of adolescents with a 
range of chronic illnesses (37–39). In SSA, a lack of social support and IPV, both of which are 
common among young women in this context, have been linked to poor adherence to ART 
(10,11).  Given the disparities in HIV incidence faced by young women in generalized HIV 
epidemic settings, the relative sparsity of adolescents in PrEP research, and low adherence as 
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an emerging barrier to PrEP’s efficacy, research is needed to identify social and behavioral 
processes specific to the implementation of PrEP in this population to facilitate adherence. 
 
Disclosure and PrEP adherence  
AGYW are likely to need support for effective PrEP use. In qualitative data from the 
VOICE trial, women identified a lack of support from family members, peers, partners, and the 
community as a contributor to their poor adherence (12). As described among young people 
living with HIV, disclosure can be an important means of eliciting social support for adherence to 
ART (40–42). While disclosure may play a similar role in facilitating adherence to PrEP, 
disclosure can also expose individuals to the harmful effects of stigma (43). Stigma has 
emerged as a significant social harm that can arise from PrEP use in acceptability studies 
(12,44–46). PrEP use risks multiple stigmas, including the stigma of being related to HIV and 
participating in high-risk behaviors (47). PrEP use can also evoke concerns that one is breaking 
the rules of the community and putting oneself at risk for violence. Information is needed on the 
effect of disclosure to various social groups on adherence to better support AGYW initiating 
PrEP and help them avoid potential violence and experiences of stigma. 
Recent qualitative research among AGYW specifically has highlighted the potential 
association between disclosure to various social groups and PrEP adherence (48–50). 
Disclosure may be an especially important factor to consider with respect to adolescents. 
Adolescent development takes place within a complex web of family, peer, community, societal, 
and cultural influences (51). Since most adolescents live at home, parents can have a strong 
influence on adolescent motivations, decisions, and behaviors relating to health (52). Older 
adolescence and young adulthood often mark a developmental transition to strong peer and 
partner relationships, which may differentially influence risk. The identification of supportive 
relationships can be leveraged to promote sustained behavior change during this period of rapid 
life transition. For AGYW, support for PrEP adherence may come from various sources. 
 
7 
Despite knowledge of the important roles various social groups play in the lives of most 
adolescents, there is a lack of quantitative research exploring social influences on adolescent 
adherence to PrEP. Research examining the importance of disclosure and social support to 
PrEP adherence among young African women has focused on their ability to harness support 
from male partners (14–16). Narratives from qualitative research among AGYW taking PrEP 
suggest that disclosure to partners can alter perceptions of trust in relationships and expose 
AGYW to stigma (14,49,50). Since adolescent development is guided by a diverse network of 
social influences that are likely to impact health-related behavioral decisions in different ways 
than in adults, the impact of disclosure of PrEP use to various social groups on adolescent 
adherence to PrEP should be examined quantitatively to determine which relationships should 
be leveraged to support adherence and which relationships may hinder successful PrEP use. 
 
IPV and PrEP adherence 
IPV refers to refers to any act of “physical, sexual, or psychological harm by a current or 
former partner or spouse” (53). Globally, the estimated prevalence of IPV among ever-partnered 
adolescent girls aged 15-19 years is approximately 29%, which is similar to the lifetime 
prevalence of IPV across women of all ages (30%) and indicates that IPV occurs early in a 
woman’s partnered lifetime (54). In South Africa, the prevalence of physical or sexual IPV in a 
recent cohort of adolescent girls 15-19 years was estimated to be as high as 37% (55). This 
high level of IPV prevalence among AGYW is a serious public health concern. South Africa has 
the highest rate of femicide globally, with a mortality rate from IPV of 8.8 per 100,000 women 
and half of all women who are killed being killed by their intimate partners (56). Further, IPV is 
an important contributor to the HIV epidemic globally and in South Africa in particular (57–59). 
One study found that women with violent or controlling male partners were 1.5 times more likely 
to acquire HIV compared to women who had not experienced partner violence (57).  
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In the context of violent relationships, biomedical HIV prevention options that do not 
require participation from both partners may be more acceptable than those requiring male 
involvement. In SSA, however, women who report experiences of IPV have lower adherence to 
several medication regimens, including ART (11). Lower adherence to PrEP has also been 
observed among women not infected with HIV who reported IPV in the past three months in the 
Partners PrEP study (13). The impact of IPV exposure on PrEP adherence is concerning, as 
high adherence is necessary to prevent HIV acquisition via condomless sex during periods of 
risk (60). The Partner’s PrEP study, however, was conducted among serodiscordant-partnered 
adult African women with a mean age of 33 years (13). The effect of IPV on PrEP adherence 
has not yet been examined among AGYW, a group particularly vulnerable to both IPV and HIV, 
and who have found adherence to PrEP to be challenging in several studies (8,17).  
IPV is associated with a range of negative mental health sequelae, including depression 
and trauma (61,62), which been linked to poor adherence to medication regimens including ART 
(63–68). The period of adolescence in particular corresponds to elevated risk for depression 
(69–71), and there are high rates of depression and trauma in communities disproportionately 
affected by HIV due to poverty, structural disparities, orphanhood, and family HIV illness (72–
75). Therefore, AGYW in generalized HIV epidemic settings who experience IPV may be 
particularly primed for psychological distress and thus poor adherence to PrEP. Findings from 
this research may help highlight the need for early interventions on social issues that may 





SIGNIFCANCE AND INNOVATION 
This research is both significant and innovative for several reasons: 
1) This study will explore predictors of PrEP use exclusively among AGYW. Adolescent 
needs with respect to PrEP are likely to be different from adult needs due to cognitive, 
psychological, and emotional processes unique to the adolescent developmental 
trajectory. This research is aimed at informing PrEP implementation strategies specific to 
this population which continues to experience high HIV incidence in SSA. 
2) This study will utilize a biologic marker of PrEP use. Self-reported adherence data is 
commonly used in PrEP research and is subject to recall bias and social desirability bias. 
Further, pharmacy record data, while often reported, does not indicate actual medication 
use. TFV-DP concentrations from will provide us with an objective, biologic assessment of 
PrEP adherence to inform the development of tailored PrEP delivery programs for AGYW.  
3) This study will quantitatively examine the impact of PrEP use disclosure on adherence 
among AGYW. Evidence has shown that disclosure of HIV positive status can elicit 
support for adherence to ART among adolescents and young people living with HIV (40–
42). The effect of PrEP use disclosure to various social groups on adherence to PrEP has 
yet to be examined among AGYW, a group highly susceptible to diverse social influences. 
4) This study will quantitatively examine the impact of IPV on PrEP adherence among AGYW. 
IPV is an important contributor to the HIV epidemic globally and in SSA. Recently, lower 
adherence to PrEP has been observed among HIV uninfected African women who report 
recent experiences of IPV (13). The effect of IPV on adherence to PrEP has yet to be 















CHAPTER III: METHODS 
 
OVERVIEW 
This dissertation aims to examine the relationship between 1) PrEP use disclosure to 
various social groups and PrEP adherence among AGYW in the 3P study and 2) history of IPV 
and PrEP adherence among AGYW in HPTN 082. Both studies enrolled sexually active HIV-
uninfected AGYW ages 16-25 years in southern Africa. Participants who initiated once daily oral 
PrEP were included in analyses. We first conducted descriptive analysis of PrEP use disclosure 
and IPV exposure variables. Then, for both aims, we estimated the relative prevalence of high 
PrEP adherence at months 3 and 6 among those who 1) disclosed their PrEP use during follow-
up and 2) reported a history of any IPV in the past year at enrollment. High adherence was 
defined as TFV-DP ≥700 fmol/punch at a given visit. Univariate and multivariable (adjusted) 
modified Poisson or log-binomial regression models were used to estimate prevalence ratio 
measures of association. Effects were estimated in the full study population and within younger 
and older AGYW age group strata to determine if effects were modified by age. For age 
stratification, the sample median was used to maximize balance between groups given limited 
power. Potential confounders were identified through directed acyclic graph analysis (76). 
 
CONCEPTUAL MODEL  
See Figure 3.1 for the overall conceptual model informing this study. Theoretical 
concepts from the Social Cognitive Theory were used to provide context into the association 






Figure 3.1. Conceptual model for the association between PrEP use disclosure and PrEP 
adherence (AIM 1) and IPV history and PrEP adherence (AIM 2) 
 
For AIM 1, we examined the association between disclosure of PrEP use and PrEP 
adherence. Positive or negative reinforcement following disclosure is theorized to affect PrEP 
use behavior. A positive association between disclosure and high PrEP adherence may indicate 
a supportive relationship, which can improve one’s self-efficacy and behavioral capability. A 
negative association, however, may indicate a lack of support or experienced stigma. For AIM 2, 
we examined the association between IPV and PrEP adherence. IPV can have a detrimental 
impact on a woman’s mental health (79,80), which may result in greater perceived barriers and 
reduced self-efficacy for medication adherence (81–83). In contrast, women who experience 
IPV may be more likely high adherence if they perceive their increasd risk for acquiring HIV 












Exposures: Disclosure of PrEP use in the first three and six months on PrEP & history of IPV in the past year at enrollment





Currently living with a partner
Primary sex partner past 3m




AIM 2 Risk perception
For partner disclosure only:
Current primary sex partner 

























AIM I APPROACH 
AIM I: Examine the relationship between PrEP use disclosure to various social groups and 
PrEP adherence among AGYW in the 3Ps for Prevention study 
 
Data source 
We utilized longitudinal data from the 3Ps for prevention study (NCT03142256) (17). 3P 
was a NIMH funded pilot prospective cohort study evaluating PrEP uptake and adherence 
among young South African women. 200 AGYW who accepted to take daily oral PrEP were 
enrolled into 3P and followed for 12 months. Characteristics of 3P are outlined in Table 3.1.  
 
Table 3.1. Characteristics of the 3Ps for Prevention study (AIM 1) 
Title A Pilot Prospective Cohort Evaluation of Uptake and Adherence to PrEP in Young South 
African Women: The 3Ps for Prevention Study (Perception, Partners, Pills) 
Purpose 
 
To assess the interest in and adherence (including uptake, initiation, execution, and 
continuation) to daily oral PrEP among young South African women 
Objectives Primary objective: 
1) To assess the effect of an incentive provided at months 2 and 3 and conditioned on 
young women’s PrEP adherence, measured by tenofovir drug levels 
Secondary objectives: 
1) To explore factors, including knowledge of current partner HIV status, that influence 
young women’s PrEP initiation and adherence over 12 months 
2) To assess social benefits and harms associated with PrEP use 
Design 
 
A pilot prospective cohort evaluation to assess PrEP acceptability and adherence among 
200 HIV-uninfected young women who are offered open-label daily oral PrEP, 
randomized to receive (or not receive) a short-term conditional incentive. The incentive 
provided at months 2 and 3 was conditioned on tenofovir levels in their blood from the 1- 
and 2-month visits with the goal to support early habit formation with daily PrEP. 
Population Sexually active HIV-uninfected women ages 16-25 years 
Study site Masiphumelele township, Cape Town, South Africa 
Duration All participants were followed for 12 months with visits at months 1, 2, 3, 6, 9, and 12 
PrEP 
regimen 
All participants were offered once daily oral emtricitabine 200 mg / tenofovir disoproxil 





We examined effects of PrEP use disclosure on PrEP adherence among AGYW in 3P. 
Analyses were conducted among the 200 3P participants, all of whom initiated PrEP at 
baseline/enrollment. Study variables (exposures, covariates, and outcomes) were assessed at 
baseline and follow-up visits occurring 1-, 2-, 3-, and 6-months post-PrEP initiation.  
 
Study population 
Sexually active HIV-uninfected AGYW in Masiphumelele township, Cape Town, South 
Africa who were not currently enrolled in any other research studies and had not previously 
participated in an oral PrEP study were eligible to enroll in 3P. Masiphumelele is a peri-urban 
settlement of approximately 30,000 people found 40 km south of Cape Town in the Southern 
Peninsula district in South Africa’s Western Cape province. The 3P study was conducted at a 
research center located at a youth-friendly clinic in the Masiphumelele township.  
Participants were eligible if they were (1) female at birth; (2) HIV uninfected at screening 
and enrollment; (3) aged 16-25 years at screening; (4) per participant report, sexually active, 
defined as having vaginal or anal intercourse with a male partner at least once in the month 
prior to enrollment; (5) intending to take PrEP; (6) willing and able to provide informed consent; 
(7) willing to provide adequate locator information; and (8) Tanner Stage ≥ 3.  
 
Variable assessment 
All behavioral assessments were integrated into a single questionnaire that was 
administered via computer-assisted self-interview (CASI) software at baseline and all follow-up 





Table 3.2. Exposure, outcome, and covariate measures for AIM 1 
Variable Measures BL Follow-up (month) 1 2 3 6 
Exposure: PrEP use 
disclosure  
Self-reported disclosure of PrEP 
use since last study visit 
 ü ü ü ü 
Outcome: High PrEP 
adherence  
TFV-DP concentrations in dried 
blood spot samples 
   ü ü 
Covariates: Trial arm, age, 
disclosure of PrEP plans at 
enrollment, current primary 
sex partner, history of IPV  
Self-reported DOB, disclosure of 
PrEP intentions, having a primary 
sexual partner, and experiencing 
IPV in the past year at enrollment 
ü     
 
Exposure assessment 
Disclosure of PrEP use was assessed using self-report data. At follow-up visit months 1, 
2, 3, and 6, participants were asked if they had told anyone about their PrEP use since their last 
visit (yes/no). Participants who responded affirmatively were then asked if they had disclosed 
their PrEP use separately to at least one person in each of several specific social groups: a sex 
partner, a parent, a sister or brother, an “other family member”, a friend, a neighbor, a nurse or 
doctor, and “other” persons. For each specific social group to which a participant reported 
disclosing her PrEP use to at least one person, she received an additional question inquiring if 
she received a supportive reaction in that group. Disclosure was assessed at two time points: 
within the first three months of follow-up (i.e., disclosure of PrEP use reported at months 1, 2, or 
3) and within the first six months of follow-up (i.e., disclosure of PrEP use reported at months 1, 
2, 3, or 6). See Appendix A for the full disclosure questionnaire.  
 
Disclosure was defined in several ways: 
1) A binary (yes/no) disclosure to anyone variable representing disclosure of PrEP use to at 
least one person within the first three and six months of follow-up. 
2) A continuous sum variable representing the total number of different social groups a 
participant reported disclosing to within the first three and six months of follow-up. 
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3) Discrete, binary (yes/no) disclosure variables representing disclosure to at least on sex 
partner, parent, and friend within the first three and six months of follow-up. 
 
Outcome assessment 
The primary outcome, high PrEP adherence, was measured using dried blood spots 
(DBS) collected at study visits occurring at 3- and 6-months post-PrEP initiation. DBS are a 
reliable measure of cumulative adherence that can be used to detect intracellular levels of 
tenofovir-diphosphate (TFV-DP) for adherence monitoring in the month prior to a sample being 
collected (17-day half-life for TFV-DP and 25-fold accumulation to steady state) (85). Consistent 
with other studies, gradients for adherence include: a TFV-DP DBS level of ≥1,250 fmol/punch 
(daily dosing), 700-1249 fmol/punch (4-6 tablets per week), 350-699 fmol/punch (2-3 tablets per 
week), ≤349 fmol/punch (<2 tablets per week), and below limit of quantification (<16.6 
fmol/punch) (2,85). TFV-DP ≥700 fmol/punch was associated with 100% efficacy among MSM 
in the iPrEX OLE study and correlates with taking an average of at least four doses per week in 
the prior month based on directly observed dosing (2,86). We will examine high PrEP 
adherence, defined as DBS TFV-DP ≥700 fmol/punch, at months 3 and 6. 
 
Covariate assessment 
Potential covariates, theorized using a directed acyclic graph (76) (see Figure 3.2), 
included parent study trial arm, age, and disclosure of intentions to use PrEP prior to enrollment. 
For disclosure to a partner specifically, having a primary sexual partner and history of intimate 
partner violence (IPV) in the past year were also included. All covariates were assessed at 










We conducted descriptive analyses of demographic and behavioral characteristics 
assessed prior to PrEP initiation at enrollment/baseline or, if not available, at screening. 
Participant characteristics included age, education level (screening only), having a primary 
sexual partner, HIV status of primary partner, history of any IPV in the past year, and worry 
about getting HIV. We then determined the proportion of participants who reported disclosing to 
anyone and to at least one member of a given social group during the first three and six months 
of follow-up, as well as the proportion of participants who received at least one supportive 
reaction following disclosure to at least one member of a given social group. For each social 
group, we also calculated at each visit the number of participants with a new group-level 
disclosure, defined as a reported disclosure since the last visit to at least one person in a given 






Main causal pathway examined
Theorized mediating pathways 
Theorized confounding pathways 
For partner disclosure only:
Current primary sex partner 





Disclosure of PrEP plans
Potential confounders assessed at enrollment:
Having a living parent
Household members
Potential confounders not assessed:
[Minimally sufficient adjustment set]
Potential mediators (not examined):
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each group. To determine if PrEP use disclosure varied by age, we used log-binomial 
regression to estimate a prevalence ratio (PR) for disclosure of PrEP use to each social group in 
the first 6 months of follow-up for younger (≤18 years) versus older (>18 years) AGYW.   
Next, we described the proportion of participants with high adherence at months 3 and 6.  
In primary analyses, participants with a missing DBS result (either due to missing the study visit 
or not providing a DBS) were imputed as non-adherent under the assumption that they were 
likely to have stopped taking PrEP. We probed the impact of this assumption in sensitivity 
analyses (described below). We then used modified Poisson regression with a robust error 
variance (89) to estimate the relative prevalence of high adherence among those who disclosed 
their PrEP use compared to those who did not disclose their PrEP use. With these PR 
estimates, we examined associations between 1) disclosure of PrEP use over the first three 
months of follow-up and high adherence at month 3, and 2) disclosure of PrEP use over the first 
six months of follow-up and high adherence at month 6. For both the three-month and six-month 
outcomes, we examined the overall impact on adherence of PrEP use disclosure to anyone and 
to a greater number of different social groups. To reduce bias, we then identified potential 
confounders of the disclosure-adherence relationship using a directed acyclic graph (see Figure 
3.2) (76), and we included available covariates in multivariable models to calculate adjusted PR 
(aPR) estimates. All full sample adjusted models controlled for age, trial arm, and disclosure of 
intentions to use PrEP reported at enrollment prior to actual PrEP use. 
Then, because we hypothesized that the effects of disclosure to certain groups might 
vary by age (i.e., younger AGYW who are more likely to be living at home and/or in school may 
obtain support from different social groups than older AGYW), we calculated overall and age-
stratified PR estimates separately for disclosure to parents, partners, and peers, and we 
assessed for evidence of effect measure modification by age by including an interaction term 
(disclosure ´ dichotomous age group) in adjusted regression models. A Wald test with an alpha 
value of 0.15 was used to assess the statistical significance of the interaction. The age 
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categorization of ≤18 and >18 years maximized balance between groups given our limited 
sample size. Age-stratified models adjusted for trial arm and enrollment disclosure. In models 
examining disclosure to partners, we also adjusted for participants having a primary sex partner 
and history of any IPV in the past year, both of which were assessed at enrollment. For all full-
sample and age-stratified PR and aPR estimates, an effect was considered statistically 
significant if the 95% confidence intervals (CIs) did not overlap the null value of 1.0.  
 
Missing data 
Missing data was expected to be primarily related to missed visits or loss to follow-up. 
We expected this type of missing data to be missing not at random (MNAR), such that 
participants who were less adherent would be more likely to be missing (see Figure 3.2). With 
MNAR data, our primary analytical recourse was to utilize observed data only and conduct a 
sensitivity analysis (90). However, missing outcome data was substantial (17% at month 3 and 
31% at month 6), and by restricting our sample to those who are not missing outcome data, we 
would essentially be observing a stratified random sample within strata of our outcome and thus 
introducing bias. Given this knowledge, for primary analyses, we used single imputation of 
missing outcome data as non-adherence under the assumption that participants who missed 
their month 3 or 6 visit were thought likely to have stopped taking PrEP and, therefore, would 
have had low drug concentration if a DBS had been obtained. We then probed the impact of this 
assumption in a complete-case and a last observation carried forward sensitivity analysis.  
 
 




 To assess the sensitivity of results to our primary analysis assumption that missing DBS 
values represented non-adherence, we conducted a complete-case and last observation carried 
forward sensitivity analysis. In our complete-case sensitivity analysis, we restricted our analytic 
sample to participants with an available DBS result at a given time point. In our last observation 
carried forward sensitivity analysis, participants with a missing TFV-DP result were imputed with 
the TFV-DP result from their previous visit. If PrEP was held ≥30 days before the visit date, the 
participant was instead imputed as non-adherent. If PrEP was not held ≥30 days before the visit 
date and a participant had a missing TFV-DP result at their previous visit, no value was imputed 
(i.e., observations were still coded as missing). 
 
Software 
All statistical analyses were conducted in SAS software, version 9.4 (Cary, NC). 
 
Ethical approval  
3P study procedures were approved by the University of Cape Town’s Human Research 
Ethics Committee and this analysis was approved by the University of North Carolina at Chapel 
Hill’s Institutional Review Board. All participants provided written informed consent in English or 






AIM II APPROACH 
AIM II: Examine the relationship between history of IPV and PrEP adherence among AGYW in 
the HIV Prevention Trials Network 082 study 
 
Data source  
We utilized longitudinal data from the HIV Prevention Trials Network 082/HERS study 
(HPTN 082) (NCT02732730) (18). HPTN 082 was a Phase IV randomized multi-site prospective 
study designed to assess PrEP uptake and adherence among HIV-uninfected young women. A 
total of 451 AGYW who were interested in daily oral PrEP were enrolled into HPTN 082 and 
followed for 12 months. Characteristics of HPTN 082 are outlined in Table 3.3. 
 
Table 3.3. Characteristics of the HIV Prevention Trials Network 082 study (AIM 2) 
Title  Uptake and adherence to daily oral PrEP as a primary prevention strategy for young 
African women: A Vanguard Study (HPTN 082/HERS) 
Purpose To assess the acceptance rate, adherence, acceptability, and continuation of oral pre-
exposure prophylaxis (PrEP) among young southern African women 
Objectives Primary objectives: 
1) To assess the proportion and characteristics of young HIV-uninfected women who 
accept versus decline PrEP at enrollment 
2) To assess the difference in PrEP adherence using drug levels in young women 
randomized to the enhanced versus standard arms 
Design A Phase IV randomized multi-site prospective study to assess open-label daily oral 
PrEP acceptance and adherence among HIV-uninfected young women. All women 
who accepted PrEP were randomized 1:1 to receive enhanced adherence counselling 
based on feedback from observed drug levels or standard adherence support.  
Population Sexually active HIV-uninfected women ages 16-25 years 
Study sites Spilhaus Clinical Research Site in Harare, Zimbabwe  
The Emavundleni Research Centre in Cape Town, South Africa  
Wits Reproductive Health and HIV Institute (Wits RHI) in Johannesburg, South Africa 
Duration All participants were followed for 12 months with visits at months 1, 2, 3, 6, 9, and 12 
PrEP 
regimen  
All participants were offered once daily oral emtricitabine 200 mg / tenofovir disoproxil 





We examined the effects of IPV history on PrEP adherence among AGYW in HPTN 082. 
Analyses were conducted among the 411 participants who accepted and initiated PrEP at 
baseline/enrollment. Study variables (exposures, covariates, and outcomes) were assessed at 
baseline and follow-up visits occurring at 3- and 6-months post-PrEP initiation.  
 
Study population 
Sexually active HIV-uninfected AGYW were enrolled in HPTN 082 across 3 study sites: 
the Spilhaus Clinical Research Site in Harare, Zimbabwe, the Emavundleni Research Centre in 
Cape Town, South Africa and Wits Reproductive Health and HIV Institute (RHI) in 
Johannesburg, South Africa. Individuals were eligible if they were 1) female at birth; 2) aged 16-
25 years; 3) per participant report, sexually active, defined as having vaginal or anal intercourse 
at least once in the month prior to screening; 4) literate in one or more of the study languages; 
5) willing and able to provide informed consent or assent (if parental consent is required per 
local regulations); 6) if parental consent is required per local regulations, parent/legal guardian 
willing and able to consent to all study procedures including HIV testing; 7) able and willing to 
provide adequate locator information; 8) have a score of 5 or greater on the VOICE risk score 
tool; 9) have interest in PrEP; 10) have regular access to a mobile phone with SMS capacity; 
11) agree not to participate in other research studies involving drugs or medical devices for the 
next 12 months; and 12) Hepatitis B virus (HBV) seronegative and accepts HBV vaccination. 
Individuals were excluded if they were 1) currently pregnant or planning to become pregnant; 2) 
had a health condition that could interfere with study participation including renal dysfunction or 
an infection; 3) reported any PrEP use within the past 12 months; or 4) had any positive or 





All behavioral assessments were integrated into a single questionnaire that was 
administered via computer-assisted self-interview (CASI) software at baseline and follow-up 
visits. Exposure, outcome, and covariate measures utilized for AIM 2 are shown in Table 3.4. 
 
Table 3.4. Exposure, outcome, and covariate measures for AIM 2 
Variable Measures BL Follow-up (month) 3 6 
Exposure: History of any IPV in 
the past year by a current or most 
recent partner 
Self-reported in 4-item IPV 
questionnaire 
ü   
Outcome: High PrEP adherence TFV-DP concentrations in 
dried blood spot samples 
 ü ü 
Covariates: Study site, age, 
education, food security, prior 
pregnancy, currently living with a 
partner, primary sex partner past 
3m, transactional sex past 3m 
Self-reported DOB, 
education level, food 
security, ever pregnant, 
housing, partnership 
questions; transactional 
sex questionnaire  
ü   
 
Exposure assessment 
History of IPV was assessed using self-report data. At baseline (enrollment), IPV was 
measured using four items inquiring about physical, emotional, sexual, and psychological IPV 
occurring in the past year. For physical IPV, participants were asked, “In the past year, has your 
current or most recent partner punched, slapped, kicked, or bit you, or caused you any type of 
physical harm?”; for emotional IPV, participants were asked, “In the past year, has your current 
or most recent partner insulted, ignored or humiliated you, yelled at you, or made you feel 
ashamed or bad about yourself?”; for sexual IPV, participants were asked, “In the past year, has 
your current or most recent partner forced you to have sex or perform any sexual act, or 
touched you sexually in any way that you did not want?”; and for psychological IPV, participants 
were asked, “In the past year, has your current or most recent partner made you feel afraid, 
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unsafe or in danger?”. Participants could respond “yes”, “no”, or “prefer not to answer” for each 
IPV item. See Appendix B for the full IPV questionnaire.  
 
Exposure to IPV was defined in several ways:  
1) A binary (yes/no) any IPV variable representing a history of any IPV in the past year 
reported at baseline. If a participant responded in the affirmative to at least one IPV 
question of any type, she was coded as having reported experiencing any IPV by a 
current or most recent partner in the year prior to baseline. Participants were coded as 
not having reported experiencing any IPV if they responded “no” to all four question 
types. Otherwise, participant exposure status was coded as missing. 
2) discrete, binary (yes/no) IPV variables representing a history of each of the four IPV 
types (physical, emotional, sexual, and psychological IPV) in the past year.  
 
Outcome assessment 
Similar to AIM 1, the primary outcome, high PrEP adherence, was measured using DBS 
collected at study visits occurring at 3- and 6-months post-PrEP initiation. DBS are a reliable 
measure of cumulative adherence that can be used to detect intracellular levels of tenofovir-
diphosphate (TFV-DP) for adherence monitoring in the month prior to a sample being collected 
(17-day half-life for TFV-DP and 25-fold accumulation to steady state) (85). Consistent with 
other studies, gradients for adherence include: a TFV-DP DBS level of ≥1,250 fmol/punch (daily 
dosing), 700-1249 fmol/punch (4-6 tablets per week), 350-699 fmol/punch (2-3 tablets per 
week), ≤349 fmol/punch (<2 tablets per week), and below limit of quantification (<16.6 
fmol/punch) (2,85). TFV-DP≥700 fmol/punch was associated with 100% efficacy among MSM in 
the iPrEX OLE study and correlates with taking an average of at least four doses per week in 
the prior month based on directly observed dosing (2,86). We will examine high PrEP 




We used a directed acyclic graph (76) to identify potential confounders of the IPV-
adherence relationship that were hypothesized to be associated with both IPV and adherence, 
but not effects of either IPV or adherence (see Figure 3.4). Theorized covariates included 
participant age, country, education level, food security (“In the past year, how frequently did you 
worry that your household would not have enough food?”), prior pregnancy, currently living with 
a partner, having a primary sex partner in the past three months, and transactional sex in the 
past three months (“In the last 3 months, have you had sex with a man because he provided 
you with or you expected that he would provide you with: food, clothes, cosmetics, a cell phone, 
items for your child, transport, residence/school fees, lodging, cash, or other items?”). All 
theorized covariates were assessed at enrollment along with measurement of the exposure. 
Potential covariates were only included in adjusted regression models if they met the pre-
treatment criterion (i.e., if they were measured prior to the exposure) or if they could not 
plausibly be effects of the exposure (87,88). Prior pregnancy (ever), partner variables (assessed 
as current or in the past 3 months), and transactional sex in the past three months could not be 
determined to precede measurement of the exposure and thus could be effects of the exposure. 
Therefore, they were not included as covariates. Participant age, country, education level, and 
food security, were not likely effects of IPV and were thus controlled for as covariates. Trial arm, 
assigned at enrollment, was not theorized to be associated with IPV. Other participant 
characteristics, including depression (assessed using the CES-D-10) and HIV risk perception, 









We restricted the population of AGYW for analyses to participants who accepted PrEP at 
baseline to ensure consistent relationships among the timing of exposure assessment, PrEP 
initiation, and follow-up adherence measures across participants. In this analysis population, we 
first described participant demographic and behavioral characteristics assessed prior to PrEP 
initiation at enrollment or, if not available, at screening. Participant characteristics included study 
site, trial arm, age, education level (screening only), food security (worried about food in the 
past year), prior pregnancy, currently living with a partner, having a primary sex partner in the 
past three months, age difference with primary sex partner, any transactional sex in the past 
three months, clinically significant symptoms of depression (CES-D-10 score ≥12), and 




Main causal pathway examined
Theorized mediating pathways 
Theorized confounding pathways 











Currently living with a partner*
Primary sex partner past 3m*
Transactional sex past 3m*




The prevalence of any IPV by each participant characteristic was examined to determine 
IPV prevalence varied by these characteristics. T-tests with unequal variance and likelihood 
ratio chi-square tests (LRTs) were used to test significance for continuous and categorical 
participant characteristics, respectively. We then described baseline IPV prevalence, including 
each individual IPV type and any IPV across all types, in the full sample and within age strata. 
Among AGYW who reported any IPV, we further described the proportion of participants who 
reported experiencing a single type of IPV, two types, three types, and all four types.  
Next, we described the proportion of AGYW with high adherence at months 3 and 6. In 
primary analyses, participants with a missing DBS result were imputed as non-adherent under 
the assumption that they were likely to have stopped taking PrEP (as the majority of missing 
DBS results were due to participants missing their study visit). We probed the impact of this 
assumption in several sensitivity analyses (described below). We then constructed univariate 
and multivariable (adjusted) log-binomial regression models to estimate the overall relative 
prevalence of high adherence at months 3 and 6 (separately) among those who reported vs. did 
not report any IPV in the past year. We identified potential confounders using a directed acyclic 
graph (see Figure 3.4) (76). Models controlled for age, country, education, and food security.  
Then, since adolescence is a period characterized by rapid biological and psychological 
development (51), and younger AGYW may have less experience negotiating with partners and 
thus be particularly vulnerable to the negative effects of IPV, we hypothesized that effects on 
adherence of IPV might vary by age. To test this, we calculated age-stratified prevalence ratio 
(PR) estimates and assessed for evidence of effect measure modification by including an 
interaction term in univariate and multivariable regression models. A Wald test with an alpha 
value of 0.15 was used to assess the statistical significance of the interaction. We dichotomized 
age at the median to ensure age groups had sufficient numbers of participants for comparison. 
Age-stratified models adjusted for country, education level, and food security. 
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Last, in ancillary analyses aiming to assess relationships between specific IPV types and 
PrEP adherence, we separately estimated PRs for high PrEP adherence according to reporting 
of each IPV type (physical, emotional, sexual, psychological) vs. no reporting of that specific IPV 
type. Adjusted ancillary models controlled for age, country, education level, and food security. 
 
Missing data 
Similar to AIM 1, missing data was expected to be primarily related to missed visits or 
loss to follow-up. We expected this type of missing data to be missing not at random (MNAR), 
such that participants who were less adherent would be more likely to be missing (see Figure 
3.2). With MNAR data, our primary analytical recourse was to utilize observed data only and 
conduct a sensitivity analysis (90). However, missing outcome data was substantial (13% at 
month 3 and 15% at month 6), and by restricting our sample to those who are not missing 
outcome data, we would essentially be observing a stratified random sample within strata of our 
outcome and thus introducing bias. Given this knowledge, for primary analyses, we used single 
imputation of missing outcome data as non-adherence under the assumption that participants 
who missed their month 3 or 6 visit were thought likely to have stopped taking PrEP and, 
therefore, would have had low drug concentration if a DBS had been obtained. We probed the 
impact of this assumption in a complete-case and Monte Carlo probabilistic sensitivity analysis.  
 
 






We conducted sensitivity analyses to assess the potential bias associated with estimates 
derived from our primary models, which utilized single imputation for missing outcome data 
under the assumption that missing data reflected non-adherence. First, we conducted a 
probabilistic sensitivity analysis using a Monte Carlo simulation (91,92) in which a total of 
10,000 values were generated using a trapezoidal distribution with parameters designed to 
reflect our reasonable certainty that 75% to 95% of observations with a missing outcome were 
actually non-adherent (meaning that we assume a small but nonzero proportion of study 
participants without adherence data were actually still adherent to PrEP), with bounds of 70% 
(minimum) and 100% (maximum). Women with missing adherence values were then randomly 
assigned an adherence status from this distribution. In HPTN 082, 83-87% of AGYW with a 
missing DBS result at months 3 and 6, respectively, had missed their study visit and were 
thought to have likely stopped taking PrEP. We used this information to inform the probability of 
non-adherence specified in our simulation. For our second sensitivity analysis, we conducted a 
complete case analysis by restricting our sample to participants with a DBS result. 
 
Software 
All statistical analyses were conducted in SAS software, version 9.4 (Cary, NC). 
 
Ethical approval  
HPTN 082 study procedures were approved by the Institutional Review Boards (IRBs) of 
the University of California at San Francisco, the University of Washington, and each study site.  
This analysis was approved by the University of North Carolina at Chapel Hill IRB. All 
participants provided written informed consent in their preferred language. A parental consent 











CHAPTER IV: THE EFFECT OF PREP USE DISCLOSURE ON ADHERENCE IN A COHORT 
OF ADOLESCENT GIRLS AND YOUNG WOMEN IN SOUTH AFRICA 
 
INTRODUCTION 
Adolescent girls and young women (AGYW) represent a population at high risk of 
acquiring HIV infection (1). In sub-Saharan Africa, where the vast majority of infections occur 
globally, nearly 25% of all new HIV infections occur among AGYW, and AGYW are more than 
twice as likely to become infected with HIV compared to young men (1,93). AGYW are at a 
decisive age in their developmental trajectories, often facing milestones such as sexual debut 
and increased engagement in sexual partnerships. Thus, AGYW critically need access to a 
range of HIV prevention options, including biomedical HIV prevention strategies, along with 
information and skills to facilitate sexual decision-making (19,94,95). 
 Oral antiretroviral pre-exposure prophylaxis (PrEP) is an effective biomedical HIV 
prevention strategy that holds enormous potential to substantially reduce HIV acquisition in 
diverse populations globally (23). Evolving data from randomized trials and demonstration 
projects among adult men have shown a reduction in HIV acquisition of greater than 90% with 
oral PrEP when adherence is high, with the majority of breakthrough infections occurring among 
those who discontinue PrEP (2–4) Among young African women, however, adherence has been 
challenging, compromising PrEP efficacy in two trials (5,6). Further, adolescents <18 years of 
age have only recently been included in biomedical HIV prevention studies, and thus there is 
limited understanding of factors impacting adherence in this young age group (7,8,18,28). 
AGYW are likely to need support for effective PrEP use. As described among young 
people living with HIV, disclosure can be an important means of eliciting social support for 
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adherence to antiretroviral therapy (40,42). Research examining the importance of disclosure 
and social support to PrEP adherence among African women has focused on their ability to 
harness support from male partners (14–16). In the transition to young adulthood, adolescent 
development is guided by a diverse network of social influences that are likely to impact health-
related behavioral decisions in different ways than in adults (51,52,96). To better support AGYW 
initiating PrEP, information is needed on the effect of disclosure to specific social groups, 
including parents, partners, and peers, on PrEP adherence. In this study, we sought to examine: 
1) PrEP use disclosure by AGYW to specific social groups, and 2) the effect of PrEP use 
disclosure on PrEP adherence, both overall and according to age. 
 
METHODS 
Parent trial design 
We used longitudinal data from the 3Ps for Prevention study (3P), a randomized trial 
evaluating PrEP acceptability and adherence among South African AGYW (17). Between March 
2017 and March 2018, 200 AGYW aged 16-25 years who were enrolled into 3P initiated daily 
oral PrEP and were followed monthly for 3 months and then quarterly through month 12. At 
enrollment, participants were randomized 1:1 to receive (or not) a short-term incentive 
conditional on tenofovir-diphosphate (TFV-DP) concentrations in dried blood spots (DBS) to 
promote adherence. Additional detail on the study is provided elsewhere (17). 
 
Study population and procedures 
3P was conducted at a youth-friendly research center located in a peri-urban township of 
approximately 30,000 people 40 km outside Cape Town in the Southern Peninsula district of 
South Africa’s Western Cape province. Participants were recruited through a social marketing 
campaign to raise PrEP awareness, educate AGYW about PrEP, and enumerate PrEP demand 
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(97). Sexually active, HIV-uninfected AGYW aged 16-25 years who were not currently enrolled 
in any other research studies, had not previously participated in an oral PrEP study, and were 
intending to take PrEP for up to 12 months were eligible to enroll into the 3P study.  
AGYW who met the inclusion criteria and consented to study participation were offered 
once-daily oral emtricitabine 200 mg / tenofovir disoproxil fumarate 300 mg (FTC/TDF). PrEP 
was dispensed at months 1, 2, 3, 6, and 9. At each visit, participants received counseling on the 
importance of high PrEP adherence, information on potential side effects, and strategies for 
confidential storage of pills and anticipated barriers to adherence. All participants were 
compensated with a 100 ZAR shopping voucher (approximately 7 USD) at each visit, with those 
in the incentive arm having conditional opportunities to receive up to three additional vouchers. 
3P study procedures were approved by the University of Cape Town’s Human Research 
Ethics Committee and this analysis was approved by the University of North Carolina at Chapel 
Hill’s Institutional Review Board. All participants provided written informed consent in English or 
isiXhosa. A parental consent waiver was granted for participants aged 16-17 years. 
 
Data collection 
Socio-demographic data were collected from all participants prior to initiating PrEP. At all 
follow-up visits, participants completed a behavioral survey that assessed partnership 
characteristics, disclosure of PrEP use, and reactions participants received following disclosure 
events. Disclosure of PrEP use was assessed by asking participants if they had told anyone 
about their PrEP use since their last visit (yes/no). Participants who responded affirmatively 
were then asked if they had disclosed their PrEP use separately to at least one person in each 
of several specific social groups: a sex partner, a parent, a sister or brother, an “other family 
member”, a friend, a neighbor, a nurse or doctor, and “other” persons. For each specific social 
group to which a participant reported disclosing her PrEP use to at least one person, she 
received an additional question inquiring if she received a supportive reaction in that group. 
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DBS were collected at follow-up months 1, 2, 3, 6, and 12 for storage and retrospective drug-
level testing for the main study, further described under “Outcome assessment” below. 
 
Exposure assessment 
We assessed our exposure, PrEP disclosure, at two timepoints: month 3 and month 6. 
At month 3, participants who reported disclosing their PrEP use at follow-up months 1, 2, or 3 
were considered exposed. At month 6, those who reported disclosing at months 1, 2, 3, or 6 
were considered exposed. We created several exposure variables to capture different 
dimensions of disclosure that could be associated with PrEP adherence. First, to assess 
disclosure to at least one person, we created a binary ‘disclosure to anyone’ variable (yes/no). 
Second, to assess the total number of different social groups to which a participant reported 
disclosing to at least one member, we created a continuous ‘sum of disclosure groups’ variable 
(range=0-8). Third, to assess disclosure to at least one parent, partner, and friend, we created 
three separate binary disclosure variables (yes/no) for each social group. 
 
Outcome assessment 
Intracellular TFV-DP levels in DBS were measured at the University of Cape Town 
Division of Clinical Pharmacology Laboratory, which developed and validated an indirect 
method for the quantification of TFV-DP in 50 µl human DBS, in collaboration with the University 
of Colorado Pharmacology laboratory, which developed the assay and determined thresholds 
with directly observed dosing (86). DBS provide a reliable measure of cumulative PrEP 
adherence in the month prior to a sample being collected (86). We assessed our outcome, high 
adherence, at months 3 and 6 for all participants. High adherence was defined as TFV-DP ≥700 
fmol/punch at a given visit. This threshold correlated with an average of ≥4 doses/week in the 
prior month and was associated with 100% protection against HIV acquisition among men who 
have sex with men (MSM) in iPrEX OLE (2,86). In primary analyses, participants with a missing 
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DBS result (either due to missing the study visit or not providing a DBS) were imputed as non-
adherent under the assumption that they were likely to have stopped taking PrEP. We probed 
the impact of this assumption in sensitivity analyses (described below).  
 
Statistical analysis  
We conducted descriptive analyses of demographic and behavioral characteristics 
assessed prior to PrEP initiation. We then determined the proportion of participants who 
reported disclosing to anyone and to at least one member of a given social group during the first 
three and six months of follow-up, as well as the proportion of participants who received at least 
one supportive reaction following disclosure to at least one member of a given social group. For 
each social group, we also calculated at each visit the number of participants with a new group-
level disclosure, defined as a reported disclosure since the last visit to at least one person in a 
given social group. We then assessed the cumulative number of group-level disclosures over 
time for each group. To determine if PrEP disclosure varied by age, we used log-binomial 
regression to estimate a prevalence ratio (PR) for disclosure of PrEP use to each social group in 
the first 6 months of follow-up for younger (≤18 years) versus older (>18 years) AGYW.   
Modified Poisson regression with a robust error variance (89) was used to estimate the 
relative prevalence of high adherence among those who disclosed their PrEP use compared to 
those who did not. With these PR estimates, we examined associations between 1) disclosure 
of PrEP use over the first three months of follow-up and high adherence at month 3, and 2) 
disclosure of PrEP use over the first six months of follow-up and high adherence at month 6. For 
both the three-month and six-month outcomes, we examined the overall impact on adherence of 
PrEP use disclosure to anyone and to a greater number of different social groups. To reduce 
bias, we then identified potential confounders of the disclosure-adherence relationship using a 
directed acyclic graph (76), and we included available covariates in multivariable models to 
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calculate adjusted PR (aPR) estimates. All full sample adjusted models controlled for age, trial 
arm, and disclosure of intentions to use PrEP reported at enrollment. 
Then, because we hypothesized that the effects of disclosure to certain groups might 
vary by age (i.e., younger AGYW who are more likely to be living at home and/or in school may 
obtain support from different social groups than older AGYW), we calculated overall and age-
stratified PR estimates separately for disclosure to parents, partners, and friends, and we 
assessed for evidence of effect measure modification by age by including an interaction term 
(disclosure ´ dichotomous age group) in adjusted regression models. A Wald test with an alpha 
value of 0.15 was used to assess the statistical significance of the interaction. The age 
categorization of ≤18 and >18 years maximized balance between groups given our limited 
sample size. Age-stratified models adjusted for trial arm and enrollment disclosure. In models 
examining disclosure to partners, we also adjusted for participants having a primary sex partner 
and history of any intimate partner violence (IPV) in the past year, both of which were assessed 
at enrollment to ensure they preceded assessment of the exposure. For all full-sample and age-
stratified PR and aPR estimates, an effect was considered statistically significant if the 95% 
confidence intervals (CIs) did not overlap the null value of 1.0.  
Finally, to assess the sensitivity of results to our primary analysis assumption that 
missing DBS values represented non-adherence, we conducted a complete-case and last 
observation carried forward sensitivity analysis. In our complete-case sensitivity analysis, we 
restricted our analytic sample to participants with an available DBS result at a given time point. 
In our last observation carried forward sensitivity analysis, participants with a missing TFV-DP 
result were imputed by carrying forward the TFV-DP result from their previous visit. If PrEP was 
held ≥30 days before the visit date, the participant was instead imputed as non-adherent. If 
PrEP was not held ≥30 days before the visit date and a participant had a missing TFV-DP result 
at their previous visit, no value was imputed (i.e., missing outcome observations were still coded 




Sample characteristics and patterns of PrEP use disclosure  
 The 200 3P participants had a median age of 19 years (IQR=17-21) (Table 4.1). Most 
(86%) had a primary sex partner at screening, of whom 42% did not know their partner’s HIV 
status. Over half (55%) of participants were worried “a lot” about getting HIV. During the first 3 
months of follow-up, 90% of participants reported disclosing their PrEP use to at least one 
person, with 82% reporting disclosure to at least one friend, 56-59% reporting disclosure to at 
least one parent, partner, sibling or other family member (separately), 27% reporting disclosure 
to at least one neighbor, and 8% reporting disclosure to at least one nurse or doctor (Table 4.2). 
Among participants who disclosed to at least one member of a given social group during the first 
3 months of follow-up, almost all (>96% for each group) reported that at least one disclosure 
was followed by a supportive reaction within a given group. 
 During the first 6 months of follow-up, a similar proportion of participants had reported 
disclosing their PrEP use to at least one member of a given social group as had been reported 
during the first 3 month of follow-up (Table 4.2). Further, similar to month 3, within a given social 
group, most participants (>97%) reported that at least one disclosure was followed by a 
supportive reaction. Participants reported disclosing to a median of 4 different social groups by 
both month 3 and 6 of follow-up (IQR = 2-5 and 2-6, respectively). The cumulative number of 
new group-level disclosures increased most substantially over the first three months of follow-
up, and participants reported a total of 181 group-level disclosures to parents, 176 to partners, 
192 to siblings, 194 to other family, 334 to friends, 87 to neighbors, and 20 to nurses or doctors 
through month 6 (Figure 4.1). AGYW ≤18 years were significantly more likely than AGYW >18 
years to disclose to a parent (PR=1.31, 95% CI 1.03, 1.67) (Table 4.3).  There were no other 




The effect of PrEP use disclosure on adherence at months 3 and 6 
 At months 3 and 6, 40% (80/200) and 10% (20/200) of participants were classified as 
having high adherence, respectively. Overall, we did not find a strong effect of PrEP use 
disclosure on PrEP adherence in the full study population. For example, the prevalence of high 
adherence was only about 1.3 times as high among those reporting vs. not reporting disclosure 
of PrEP use to anyone at both month 3 (aPR=1.31, 95% CI 0.66, 2.58) and month 6 (aPR=1.33, 
95% CI 0.41, 4.26) (Table 4.4). Similarly, disclosure to a greater number of different social 
groups did not appear to meaningfully affect adherence at month 3. At month 6, only a small 
effect with moderate precision was observed for a one-unit increase in the number of different 
social groups to which a participant had reported disclosing (aPR=1.21, 95% CI 0.98, 1.50). 
There were no statistically significant associations, either in the full study population or in 
the separate age strata, between high adherence and disclosure of PrEP use to a partner or a 
friend. Disclosure to a parent, however, was associated with high adherence at month 6 in the 
younger age stratum (Table 4.5). Specifically, among younger AGYW (≤18 years), disclosure of 
PrEP use to a parent was associated with high month-6 adherence (aPR=6.83, 95% CI 1.02, 
45.56). In contrast, among older AGYW (>18 years), those who disclosed their PrEP use to a 
parent were slightly less likely than those who did not disclose to a parent to have high month-6 
adherence (aPR=0.69, 95% CI 0.17, 2.90) (Wald test statistic for interaction (z)=-1.87, p=.062). 
At month 3, no meaningful associations between parent disclosure and adherence were found.  
In the complete-case sensitivity analysis, 48% (80/166) and 14% (20/138) of participants 
were classified as having high adherence at month 3 and month 6, respectively. In the last 
observation carried forward sensitivity analysis, 45% (81/181) and 15% (27/179) of participants 
were classified as having high adherence at months 3 and 6, respectively. Associations of PrEP 
use disclosure with high adherence in sensitivity analyses remained largely consistent with the 





In this study of 200 AGYW, most participants disclosed their PrEP use to at least one 
other person. During six months of follow-up, just over half of participants reported disclosing 
their PrEP use to at least one parent, partner, sibling, or other family member; a greater 
proportion reported disclosing to friends and fewer reported disclosing to neighbors and nurses 
or doctors. In response to their disclosure, the majority of participants reported at least one 
supportive reaction within a given group. Disclosure to certain groups varied by age, with 
younger AGYW more likely to disclose to a parent than older AGYW. This finding is important 
given that parents can have a strong influence on health-related motivations, decisions, and 
behaviors (52), particularly among younger AGYW who may be more likely to be living at home. 
Recent recommendations for improving PrEP adherence suggest that tailored PrEP 
delivery programs are necessary to meet the needs of African AGYW (9). In this investigation 
aimed at informing these programs, we found that disclosure of PrEP use to anyone and to a 
greater number of different social groups did not affect adherence. There are several potential 
explanations for why we did not observe a relationship between disclosure and PrEP adherence 
overall. While qualitative research has highlighted the potential association between disclosure 
and adherence among AGYW, the perceived impact of PrEP disclosure in qualitative studies 
seems to hinge upon reactions and subsequent levels of support or stigma (48–50). In the 
current study, we were not able to adequately assess support following disclosure, as the 
survey did not allow participants to report multiple reactions if they disclosed to more than one 
person within a given social group during a given time period. Further, binary (yes/no) answer 
options for supportive reactions did not capture nuance in support. From previous research, we 
know disclosure is not a binary construct (98). Although the vast majority of participants 
reported supportive reactions following disclosure experiences, qualitative data from 3P shows 
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more variability in support (49). Therefore, research is needed to understand the conditions 
under which disclosure elicits social support for PrEP adherence among AGYW.  
In our stratified analysis, effects of disclosure to a parent on adherence varied 
significantly by age. Among younger AGYW, disclosure of PrEP use to a parent was associated 
with high adherence at month 6. Among older AGYW, the reverse effect was observed. These 
findings suggest that parents may play an important role in facilitating PrEP use among younger 
AGYW. Qualitative research from the 3P study also found that disclosure to parents, and 
particularly mothers, was common, and often perceived as having either a strong positive or 
negative impact on PrEP use. Support for PrEP use from mothers was often related to whether 
they understood participant explanations of PrEP, their normative beliefs about sexual and 
reproductive health matters and pill-taking behavior more broadly, and their concerns 
surrounding the resemblance of PrEP to HIV treatment (49). More work is needed to develop 
strategies for engaging parents to support their child’s PrEP use and to understand how fears 
surrounding disclosure to parents may be impacting PrEP uptake and adherence.  
Disclosure to a partner did not appear to affect adherence in our study population. In 
PrEP and microbicide placebo-controlled trials, male partners have been shown to have a 
strong influence on African women’s product uptake and use (14–16). Among AGYW and in 
open-label studies such as 3P, however, the impact of partner disclosure may differ. Narratives 
from qualitative research suggest that disclosure to partners can alter perceptions of trust and 
expose young women to violence and stigma (14,49,50). Therefore, disclosure to partners 
should be carefully considered, and AGYW initiating PrEP should be provided with strategies for 
discreet use and non-disclosure to partners who may impede their successful PrEP use.  
The majority of AGYW disclosed to at least one friend, and disclosure to friends did not 
have a clear effect on PrEP adherence. The absence of a clear effect in our study is somewhat 
surprising, since peer support interventions have been shown to improve treatment outcomes 
among adolescents on antiretroviral therapy (99). In EMPOWER, however, adherence clubs did 
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benefit young women’s PrEP use (100). Adherence clubs and other peer support interventions 
for African AGYW should be evaluated to determine how peers can help motivate PrEP use. 
Further, providers should consider the potentially important role of peers given AGYW are 
frequent disclosers to this group (50), and research should explore which peer relationships 
(close friends vs. acquaintances) are most beneficial. For example, qualitative findings from 
POWER suggest that close friends within an AGYW’s inner circle may positively influence PrEP 
use, whereas broader friend groups may be negative influencers (101).  
We note that our sample size was small, and the proportion of participants with high 
adherence at month 6 was modest, limiting the precision of estimates and our ability to detect 
meaningful associations. Additionally, missing DBS data was common, requiring imputation of 
adherence values for analysis. Although our sensitivity analyses produced similar results, it is 
possible that missing outcome data biased our findings to some extent. There is also potential 
for exposure misclassification, as self-reported disclosure is subject to recall error and social 
desirability bias. Further, there is likely unmeasured confounding and variation in disclosure 
experience and opportunity, which may dampen the validity of causal inferences. For example, 
the survey did not ask participants who they were living with, a potentially important covariate 
that may have impacted both disclosure/non-disclosure opportunity and PrEP adherence. 
Moreover, when examining disclosure to specific social groups, we were not able to control for 
variability in disclosure to other specific group types. Finally, we based our threshold for high 
adherence on research conducted among MSM and adults (2,86). To facilitate future 
investigations of PrEP adherence among South African AGYW, research is needed to identify 
the most relevant adherence thresholds for women and AGYW specifically. 
This investigation informs several recommendations for future research. First, larger, 
open-label studies are needed to assess the effects we examined here, with the inclusion of 
additional relevant covariates and more nuanced measures of disclosure and social support. A 
larger sample would also provide more power to determine if the effects of disclosure vary by 
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age, as we observed for disclosure to parents despite limited precision. Next, the effects of 
disclosure on adherence to daily oral PrEP should be compared to the effects of disclosure on 
adherence to alternative dosing regimens (e.g., intermittent, on-demand) and formulations (e.g., 
topical, injectable, insertable) to determine if disclosure is more important for daily pill-taking 
compared to more discreet or longer-acting PrEP formulations. Last, more research is needed 
to understand barriers and facilitators to both disclosure and PrEP adherence. For example, 
qualitative research has identified stigma as a barrier to disclosure among AGYW and highlights 
the important role of multi-level PrEP programs (e.g., media campaigns, community outreach) in 
changing norms around sexuality and increasing community knowledge around PrEP (48).  
 
CONCLUSIONS 
We quantitatively investigated PrEP use disclosure and adherence in a population that 
continues to experience high HIV incidence. Despite limited power, our results suggest that 
more work is needed to understand parents’ roles as allies, and to develop strategies for 
engaging parents in their child’s PrEP use. Further, adherence support programs for AGYW 
should find ways that peers and partners can help motivate effective PrEP use, and additional 
research should be conducted to identify other drivers of PrEP adherence. Examination of the 
association between PrEP use disclosure to various social groups and adherence in larger 
cohorts with more nuanced measures of disclosure and social support could provide additional 
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Table 4.1. Participant characteristics prior to PrEP initiation 
  
N (%) or  
median (IQR) 
Total Participants 200 
Age (median, IQR) 19 (17-21) 
Age   
    ≤18 years 89 (44.5%) 
    >18 years 111 (55.5%) 
Education   
   Primary or some secondary school  113 (61.8%) 
   Completed secondary school or higher  60 (30.2%) 
Has a primary sexual partner at enrollment  
    Yes 172 (86.0%) 
    No 28 (14.0%) 
HIV status of primary sexual partner  
    HIV negative 98 (57.0%) 
    HIV positive  1 (0.6%) 
    Participant doesn’t know 73 (42.4%) 
IPV in the past year at enrollment  
    Any 37 (18.6%) 
    None 162 (81.4%) 
“How worried are you about getting HIV?”  
    Not worried 43 (21.6%) 
    Worried some  46 (23.1%) 





Table 4.2. Disclosure and social support by social group and follow-up period 
Study period 
(Total non-missing observations) 
First 3 months of follow-up 
(n=191) 
First 6 months of follow-up 
(n=193) 
Disclosed to anyone, n (%)a 172 (90%) 172 (89%) 
Disclosed to a parent, n (%)b 109 (57%) 111 (58%) 
   Supportive reaction, n (%)c 107 (98%) 109 (98%) 
Disclosed to a partner, n (%) 107 (56%) 111 (58%) 
   Supportive reaction, n (%) 107 (100%) 111 (100%) 
Disclosed to a sibling, n (%) 110 (58%) 113 (59%) 
   Supportive reaction, n (%) 109 (99%) 112 (99%) 
Disclosed to other family, n (%) 113 (59%) 114 (59%) 
   Supportive reaction, n (%) 113 (100%) 114 (100%) 
Disclosed to a friend, n (%) 156 (82%) 156 (81%) 
   Supportive reaction, n (%) 152 (97%) 152 (97%) 
Disclosed to a neighbor, n (%) 51 (27%) 54 (28%) 
   Supportive reaction, n (%) 49 (96%) 53 (98%) 
Disclosed to nurse/doctor n (%) 15 (8%) 17 (9%) 
   Supportive reaction, n (%) 15 (100%) 17 (100%) 
a % = number who disclosed to anyone / total non-missing observations 
b % = number who disclosed to at least one member of a given group / total non-missing observations 
c % = number reporting at least one supportive reaction / number who disclosed to a given group 
Participant exposure status was coded as missing if they had missing data for all visits during a given study period (i.e., month 






Table 4.3. The relative prevalence of disclosure of PrEP use in the first 6 months of follow 
among those ≤18 years versus >18 years (N=193) 
 Disclosure prevalence   
 
≤18 years >18 years PRa 95% CI 
Total, n 86 107   
Disclosed to anyone, n (%) 76 (88%) 96 (90%) 0.99 0.89, 1.09 
Disclosed to a parent, n (%) 57 (66%) 54 (50%) 1.31 1.03, 1.67 
Disclosed to a partner, n (%) 50 (58%) 61 (57%) 1.02 0.80, 1.30 
Disclosed to a sibling, n (%) 49 (57%) 64 (60%) 0.95 0.75, 1.21 
Disclosed to other family, n (%) 55 (64%) 59 (55%) 1.16 0.92, 1.46 
Disclosed to a friend, n (%) 72 (84%) 84 (79%) 1.07 0.93, 1.22 
Disclosed to a neighbor, n (%) 23 (27%) 31 (29%) 0.92 0.58, 1.46 
Disclosed to nurse/doctor n (%) 10 (12%) 7 (7%) 1.78 0.71, 4.47 
a >18 years = referent group  
PR=prevalence ratio; CI=confidence interval 
PR and aPR estimates and 95% CIs were calculated using log-binomial regression 






Table 4.4. Modified Poisson regression analysis estimating the relative prevalence of high adherence at 







Table 4.5. Overall and age-stratified modified Poisson regression analysis estimating the relative prevalence of high adherence at 




















Month 1 Month 2 Month 3 Month 6
Parent Partner Sibling Other family Friend Neighbor Nurse or doctor
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SUPPLEMENTAL TABLES AND FIGURES 
 
Sensitivity analysis outcome coding 
 
 
Table 4.6. Prevalence of high PrEP adherence by outcome coding strategy 
 Month 3  Month 6 
TFV-DP ≥700 fmol/punch, DBS Events/N %  Events/N % 
Single imputation* (primary coding) 80/200 40%  20/200 10% 
Complete-case analysis 80/166 48%  20/138 14% 
Last observation carried forward analysis 81/181 45%  27/179 15% 





Complete-case sensitivity analysis 
 
 
Table 4.7. Modified Poisson regression analysis estimating the relative prevalence of high adherence at 






Complete-case sensitivity analysis 
 
 
Table 4.8. Overall and age-stratified modified Poisson regression analysis estimating the relative prevalence of high adherence at 






Last observation carried forward sensitivity analysis  
 
 
Table 4.9. Modified Poisson regression analysis estimating the relative prevalence of high adherence at 






Last observation carried forward sensitivity analysis  
 
 
Table 4.10. Overall and age-stratified modified Poisson regression analysis estimating the relative prevalence of high adherence at 




















CHAPTER V: INTIMATE PARTNER VIOLENCE AND HIV PRE-EXPOSURE PROPHYLAXIS 
ADHERENCE AMONG YOUNG AFRICAN WOMEN IN HPTN 082 
 
INTRODUCTION 
Intimate partner violence (IPV) refers to any act of physical, sexual, emotional and/or 
psychological harm by a current or former partner or spouse (53). Globally, the estimated 
prevalence of IPV among ever-partnered adolescent girls and young women (AGYW) aged 15-
19 is approximately 29%, which is similar to the lifetime prevalence of IPV across women of all 
ages (30%) and indicates that IPV occurs early in a woman’s partnered lifetime (54). In South 
Africa, the prevalence of physical or sexual IPV in a cohort of AGYW (15-19 years) was as high 
as 37% (55), making IPV a serious public health concern. South Africa has the highest rate of 
femicide globally, with a mortality rate from IPV of 8.8 per 100,000 women and half of all women 
who are killed being killed by their intimate partners (56). Further, IPV is an important contributor 
to the HIV epidemic globally and in South Africa in particular (57–59). One study among South 
African young women found that women with violent or controlling male partners were 1.5 times 
as likely to acquire HIV as women who had not experienced partner violence (57).  
In the context of violent relationships, biomedical HIV prevention options that do not 
require participation from both partners may be more acceptable than those requiring male 
involvement. In sub-Saharan Africa (SSA), however, women who report experiences of IPV 
have lower adherence to several medication regimens, including antiretroviral therapy (ART) 
(11). Lower adherence to pre-exposure prophylaxis (PrEP) has also been observed among 
women not infected with HIV who reported IPV in the past three months in the Partners PrEP 
study (13). The impact of IPV exposure on PrEP adherence is concerning, as high adherence is 
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necessary to prevent HIV acquisition via condomless sex during periods of risk (60). The 
Partner’s PrEP study, however, was conducted among serodiscordant-partnered adult African 
women with a mean age of 33 years. The effect of IPV on PrEP adherence has not yet been 
examined among AGYW, a group particularly vulnerable to both IPV and HIV, and who have 
found adherence to PrEP to be challenging in several studies (8,17). We examined the effect of 
self-reported violence by a current or most recent partner in the year prior to PrEP initiation on 
PrEP adherence over time among AGYW in southern Africa. Findings from this research may 
highlight the need for early interventions on the effects of IPV for AGYW initiating PrEP. 
 
METHODS 
Parent trial design 
We used longitudinal data from the HIV Prevention Trials Network (HPTN) 082/HERS 
study, a Phase IV randomized multi-site prospective study designed to assess PrEP acceptance 
and adherence among sexually active HIV-uninfected AGYW in southern Africa. From October 
2016 to October 2018, AGYW ages 16-25 years were offered once-daily oral emtricitabine 
200mg / tenofovir disoproxil fumarate 300mg (FTC/TDF) and followed for up to 12 months. At 
PrEP acceptance, participants were randomized 1:1 to receive standard adherence support 
(counseling, two-way SMS communication, and peer support through adherence support clubs) 
or enhanced adherence support with counseling based on feedback from drug levels in addition 
to the standard adherence support components. Follow-up visits occurred monthly for 3 months 
post-enrollment and then quarterly through month 12. Participants who initially declined PrEP at 
enrollment were followed on the same schedule for 12 months and could choose to begin PrEP 





Study population and procedures 
In HPTN 082, AGYW were recruited at two sites in South Africa (Cape Town and 
Johannesburg) and one site in Harare, Zimbabwe. Recruitment was conducted through 
community events, schools, primary care and family planning clinics, and youth centers. HIV-
uninfected young women (16-25 years) were eligible if they were interested in PrEP; literate in 
English, isiXhosa, isiZulu, SeSotho or Shona; sexually active; and at high risk of acquiring HIV 
as determined by an empirical risk score (102). Individuals were excluded if they were currently 
pregnant or planning to become pregnant, had a health condition that could interfere with study 
participation, or reported any PrEP use within the past 12 months. AGYW who met the inclusion 
and exclusion criteria and consented to study participation were offered PrEP at enrollment. For 
participants who accepted, PrEP was dispensed again at 1, 2-, 3-, 6-, and 9-months post-PrEP-
initiation. Participants were compensated for their time and reimbursed for travel to study visits. 
Socio-demographic data were collected from all participants at a screening visit prior to 
study enrollment and PrEP initiation. At enrollment, participants we administered an electronic 
behavioral survey using Computer Assisted Self Interview (CASI) software that assessed food 
security, prior pregnancy, housing, partnership characteristics, transactional sex, depression, 
HIV risk perception, and IPV. Dried blood spots (DBS) were collected at follow-up months 3 and 
6 for storage and retrospective drug-level testing to assess adherence (see below). 
HPTN 082 study procedures were approved by the Institutional Review Boards (IRBs) of 
the University of California at San Francisco, the University of Washington, and each study site.  
This analysis was approved by the University of North Carolina at Chapel Hill IRB. All 
participants provided written informed consent in their preferred language. A parental consent 







At baseline (enrollment), IPV was assessed using four items inquiring about physical, 
emotional, sexual, and psychological IPV occurring in the past year. For physical IPV, 
participants were asked: “In the past year, has your current or most recent partner punched, 
slapped, kicked, or bit you, or caused you any type of physical harm?”; for emotional IPV, 
participants were asked: “In the past year, has your current or most recent partner insulted, 
ignored or humiliated you, yelled at you, or made you feel ashamed or bad about yourself?”; for 
sexual IPV, participants were asked: “In the past year, has your current or most recent partner 
forced you to have sex or perform any sexual act, or touched you sexually in any way that you 
did not want?”; and for psychological IPV, participants were asked: “In the past year, has your 
current or most recent partner made you feel afraid, unsafe or in danger?”. Participants could 
respond “yes”, “no”, or “prefer not to answer” for each IPV item. If a participant responded in the 
affirmative to at least one IPV question of any type, she was coded as having reported 
experiencing any IPV by a current or most recent partner in the year prior to baseline. 
Participants were coded as not having reported experiencing any IPV if they responded “no” to 
all four question types. Otherwise, participant exposure status was coded as missing.  
 
Outcome assessment 
We assessed our outcome, high adherence, using intracellular tenofovir-diphosphate 
(TFV-DP) concentrations in DBS at months 3 and 6 for all participants. DBS provide a reliable 
measure of average PrEP adherence in the month prior to a sample being collected (86). High 
adherence was defined as TFV-DP ≥700 fmol/punch at a given visit. In the iPrEX OLE study, 
this threshold correlated with an average of ≥4 doses/week in the prior month and was 
associated with 100% protection against HIV acquisition among men who have sex with men 
(MSM) (2,86). In primary analyses, participants with a missing DBS result were imputed as non-
adherent under the assumption that they were likely to have stopped taking PrEP (as the 
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majority of missing DBS results were due to participants missing their study visit). We probed 
the impact of this assumption in several sensitivity analyses (described below). 
 
Covariate assessment  
We used a directed acyclic graph (76) to identify potential confounders of the IPV-
adherence relationship that were hypothesized to be associated with both IPV and adherence, 
but not effects of either. Theorized covariates (assessed at enrollment) included participant age, 
country, education level, food security (“In the past year, how frequently did you worry that your 
household would not have enough food?”), prior pregnancy, currently living with a partner, 
having a primary sex partner in the past three months, and transactional sex in the last three 
months (“In the last 3 months, have you had sex with a man because he provided you with or 
you expected that he would provide you with: food, clothes, cosmetics, a cell phone, items for 
your child, transport, residence/school fees, lodging, cash, or other items?”). Potential 
covariates were only included in adjusted regression models if they met the pre-treatment 
criterion (i.e., if they were measured prior to the exposure) or if they could not plausibly be 
effects of the exposure (87,88). Prior pregnancy, partner variables (assessed as current or in 
the past 3 months), and transactional sex in the past three months could not be determined to 
precede measurement of the exposure and could be effects of the exposure. Therefore, they 
were not included as covariates. Trial arm, assigned at enrollment, was not theorized to be 
associated with IPV. Other participant characteristics, including depression (CES-D-10) and HIV 
risk perception, were theorized to be likely effects of IPV and were not treated as covariates. 
 
Statistical analysis  
We restricted the population of AGYW for this analysis to participants who accepted 
PrEP at baseline to ensure consistent relationships among the timing of exposure assessment, 
PrEP initiation, and follow-up adherence measures across participants.  
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In this analysis population, we first described participant demographic and behavioral 
characteristics assessed at enrollment or screening. We examined the prevalence of any IPV by 
each participant characteristic to determine whether IPV prevalence varied according to these 
characteristics, using t-tests with unequal variance for continuous predictor variables and 
likelihood ratio chi-square tests (LRTs) for categorical variables. We then described baseline 
IPV prevalence, including each individual IPV type and any IPV across all types, in the full 
sample and within age strata. Among AGYW who reported any IPV, we further described the 
proportion of participants who reported experiencing one, two, three, and all four IPV types.  
Next, we described the proportion of AGYW with high adherence at months 3 and 6. We 
constructed univariate and multivariable (adjusted) log-binomial regression models to estimate 
the overall relative prevalence of high adherence at months 3 and 6 (separately) among those 
who reported vs. did not report any IPV in the past year. Models controlled for age, country, 
education level, and food security. Then, since adolescence is a period characterized by rapid 
biological and psychological development (51), and younger AGYW may have less experience 
negotiating with partners and thus be particularly vulnerable to the negative effects of IPV, we 
hypothesized that effects on adherence of IPV might vary by age. To test this, we calculated 
age-stratified prevalence ratio (PR) estimates and assessed for evidence of effect modification 
by including an interaction term in univariate and multivariable regression models. A Wald test 
with an alpha value of 0.15 was used to assess the statistical significance of the interaction. We 
dichotomized age at the median to ensure age groups had sufficient numbers of participants for 
comparison. Age-stratified models adjusted for country, education level, and food security. 
We conducted sensitivity analyses to assess the potential bias associated with estimates 
derived from our primary models, which utilized single imputation for missing outcome data 
(expected to be missing not at random) under the assumption that missing data reflected non-
adherence. First, we conducted a probabilistic sensitivity analysis where we ran 10,000 Monte 
Carlo simulations (91,92) in which we randomly assigned an adherence status to women with a 
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missing value, with the probability of non-adherence assumed to follow a trapezoidal distribution 
(minimum: 70%, maximum: 100%; modes: 75% and 95%). For our second sensitivity analysis, 
we conducted a complete-case analysis, restricting our sample to participants with a DBS result.  
In ancillary analyses aiming to assess relationships between specific IPV types and 
PrEP adherence, we separately estimated PRs for high PrEP adherence according to reporting 
of each IPV type (physical, emotional, sexual, psychological) vs. no reporting of that specific 
type. Adjusted ancillary models controlled for age, country, education level, and food security. 
All statistical analyses were conducted in SAS software, version 9.4 (Cary, NC). 
 
RESULTS 
Sample characteristics and IPV prevalence 
A total of 451 AGYW were enrolled into HPTN 082, of whom 411 (91%) accepted PrEP 
at baseline. Two additional participants missed their baseline visit survey and were excluded 
(N=409). Median age at baseline was 21 years (IQR=19-22 years). Prevalence of IPV in the 
past year was significantly higher among participants who reported at enrollment that they were 
worried about having enough food in their household in the past year, had a prior pregnancy, 
were currently living with a partner, had a primary sex partner or had engaged in transactional 
sex in the past three months, and had clinically significant symptoms of depression (Table 5.1). 
Among those with a primary sex partner in the past three months, the average age difference 
between the primary partner and participant was 4.7 years (standard deviation (SD)=3.6 years) 
and was not significantly different between those reporting any past-year IPV (Mean=5.0, 
SD=3.7) and those reporting no past-year IPV (Mean=4.5, SD=3.6) (p=.210). 
Approximately half (49%) of AGYW reported experiencing any IPV in the past year by a 
current or most recent partner with emotional IPV being most common (37%), followed by 
physical (20%), psychological (19%), and sexual (9%) IPV (Table 5.2). IPV prevalence did not 
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vary significantly between younger (<21 years) and older (≥21 years) AGYW. Among 
participants who reported experiencing any IPV at baseline, half (50%) reported one IPV type, 
of whom the majority (60%) reported emotional IPV. Further, almost one-third of participants 
(32%) reported two IPV types, 13% reported three IPV types, and 5% reported all four IPV types 
(Figure 5.1). Among those who reported two or three IPV types, the majority reported physical 
and emotional IPV (49%) and physical, emotional, and psychological IPV (68%), respectively. 
 
The effect of IPV on PrEP adherence at months 3 and 6 
At month 3, 54 participants (13%) had a missing DBS result, of whom 45 (83%) had 
missed their month 3 visit. In primary analyses using single imputation for missing outcome 
data, 22% (90/409) of participants were classified as having high adherence. The proportion of 
AGYW who achieved high adherence at month 3 did not differ significantly between those <21 
years (19%) and ≥21 years (25%) (LRT p=.131). History of any IPV in the past year at baseline 
did not meaningfully affect month 3 adherence in the full study population (Table 5.3). Within 
separate age strata, however, history of any IPV did affect month 3 adherence (Table 5.4). 
Specifically, among AGYW <21 years, those who reported a history of IPV in the past year were 
less likely to have high month-3 adherence compared to those who reported no IPV (adjusted 
PR (aPR)=0.43, 95% CI 0.22, 0.86). In contrast, among AGYW ≥21 years, those who reported a 
history of IPV in the past year had a greater likelihood of high month-3 adherence (aPR=2.21, 
95% CI 1.34, 3.66). There was significant evidence of effect modification by age (p<.001).  
At month 6, 63 participants (15%) had a missing DBS result, of whom 55 (87%) had 
missed their month 6 visit. In primary analyses, 18% (73/409) of participants were classified as 
having high adherence. AGYW ≥21 years were more likely to have high adherence at month 6 
(22%) compared to AGYW <21 years (13%) (LRT p=.011). Similar to month 3, history of any 
IPV in the past year at baseline did not meaningfully affect adherence at month 6 in the full 
study population (Table 5.3). Within separate age strata, effects IPV history on month 6 
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adherence were in the same direction as the effects of IPV history on adherence observed at 
month 3, although estimates were smaller in magnitude and not significant (Table 5.4). Similar 
to month 3, there was significant evidence of effect modification by age (p=.128). 
In the Monte Carlo sensitivity analysis, 24% (97/409) and 20% (83/409) of participants 
were classified as having high adherence month 3 and month 6, respectively. In the complete-
case sensitivity analysis, 25% (90/355) and 21% (73/346) of participants were classified as 
having high adherence at months 3 and 6, respectively. In both analyses, the effect of any past-
year IPV history on adherence remained largely consistent with the primary analysis in direction 
and magnitude of effect (Supplemental Tables 5.5-5.9). Ancillary analysis examining the effect 
of different IPV exposure types on high PrEP adherence in the full study population found no 
statistically significant effects (Supplemental Table 5.10). On the basis of point estimates, 
however, physical IPV in the past year appeared to have a moderate effect on adherence at 
month 3 (aRR=1.45, 95% CI 0.96, 2.19) and month 6 (aRR=1.57, 95% CI 1.00, 2.48).  
 
DISCUSSION  
In this analysis we examined the effect of IPV history by a current or most recent partner 
on PrEP adherence among AGYW in southern Africa. The association between IPV and PrEP 
adherence has previously been examined among adult African women in the Partners PrEP 
study, which found that women who reported recent IPV had increased risk of low adherence 
(13). Among AGYW, who experience high rates of both IPV and HIV, and who have had trouble 
with PrEP adherence in several studies (8,17), the effect of IPV has not yet been examined.  
In our study of over 400 AGYW, the prevalence of any IPV in the past year at baseline 
was high at 49%. A similar proportion of AGYW who reported vs. did not report any IPV had 
high PrEP adherence at months 3 and 6. However, among AGYW <21 years only, those who 
reported any IPV were less than half as likely to have high PrEP adherence at month 3, while 
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among AGYW ≥21 years, those who reported any IPV were more than twice as likely to have 
high PrEP adherence at month 3. To substantiate these findings, at month 6, effect estimates 
within each age stratum were in the same direction as month-3 results. Since we would expect 
an effect’s strength to diminish over time, it is not surprising that stratum-specific estimates at 
month 6 were smaller in magnitude and not statistically significant. At both months 3 and 6, 
there was evidence of effect modification by age. Adolescence is a period of rapid development 
which can lead to new sets of behaviors relating to health. In the transition from adolescence to 
young adulthood, trajectories towards health and wellbeing are modified by social factors (51). 
The differential effect of IPV on PrEP adherence that we observed between younger and older 
AGYW may reflect the range of cognitive, psychological, and emotional processes experienced 
by AGYW in response to IPV during different stages of this unique developmental period.  
 In our sample, PrEP adherence was found to be particularly challenging for younger 
AGYW. AGYW <21 years had slightly lower rates of high adherence at both months 3 and 6 
compared to AGYW ≥21 years, and IPV negatively impacted their month-3 adherence. In SSA, 
IPV should be considered when identifying high-risk women who may benefit from an HIV 
prevention option such as PrEP (57–59). For one to obtain the protective benefits of PrEP, 
however, it must be taken consistently. There are several plausible mechanisms through which 
IPV may negatively impact a young woman’s adherence to PrEP. First, IPV has been shown to 
have detrimental impacts on women’s mental health (79,80), which can lead to suboptimal ART 
adherence (82,83). Second, when women are fearful of violence from a partner, they may be 
less likely to disclose their medication use and take their medication freely, or a partner may 
directly inhibit their care-seeking behavior (103–106). Finally, women experiencing IPV may 
have other health priorities, such as physical safety, that take precedence over adherence to a 
preventative medication (11). Younger AGYW, who may have less experience negotiating with 
partners, may also be less resilient in their behavioral intentions to take PrEP following IPV 
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events compared to older AGYW. The mechanisms responsible for this differential effect of IPV 
on PrEP adherence, however, warrant further investigation to inform intervention design.  
In our study, we did not observe any effects of past-year IPV reported at baseline on 
adherence at months 3 or 6 in the full study population. Similarly, although the Partners PrEP 
study found that IPV in the past 3 months had increased risk of low adherence, this effect did 
not persist after three months (13). Our assessment of IPV history did not capture recent IPV 
events that may have occurred during follow-up. We did not consider the relationship between 
adherence and more temporally proximate measures of IPV in our study for two reasons. First, 
although IPV in the past month was examined at months 3 and 6 in HPTN 082, we were not 
able to ascertain if IPV occurred during certain follow-up periods (i.e., months 1, 2, 4, and 5). 
Second, assessment of IPV during follow-up overlapped with adherence measurement, limiting 
our ability to establish temporality between our outcome and exposure. It is also important to 
note that HPTN 082 was conducted 8 years after the Partners PrEP study among AGYW with a 
mean age of 21 years. Therefore, findings may be temporally bound or may reflect population-
level differences between the two studies and rapidly evolving PrEP acceptability in SSA.  
In addition to our inability to estimate the effects of recent IPV exposure on adherence, 
another limitation of our study is our modest sample size and the small proportion of participants 
with high adherence at months 3 and 6, which limited the precision of estimates and our power 
to detect meaningful associations. Additionally, missing DBS data were common, requiring 
imputation of adherence values for analysis. Reassuringly, our sensitivity analyses indicated 
that our results were fairly insensitive to several different approaches to handling the missing 
data. We also note that our exposure, IPV, is a sensitive topic and may have been 
underreported by participants or subject to recall error. Finally, we based our threshold for high 
adherence on research conducted among MSM and adults (2,86). Research is needed to 
determine the most appropriate adherence thresholds for women and AGYW specifically. 
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This investigation informs several additional recommendations for future research. First, 
qualitative studies should explore the mechanisms by which IPV affects oral PrEP adherence 
among both younger and older AGYW. Next, quantitative research should explore variables on 
the causal pathway between IPV and PrEP adherence within age-specific strata to understand if 
there is a need for targeted adherence support for younger IPV victims, and which factors we 
can intervene upon to optimize adherence in this particularly vulnerable group. Last, the effects 
of IPV on adherence to daily oral PrEP should be compared to the effects of IPV on effective 
use of alternative dosing regimens and modalities to determine if certain PrEP formulations are 
more appealing to AGYW with violent (or potentially violent) partners. Long-acting injectable 
cabotegravir, for example, offers HIV protection without relying on adherence to a daily tablet. 
 
CONCLUSIONS 
We quantitatively investigated the effect of past-year IPV history by a current or most 
recent partner on PrEP adherence in a population that continues to experience high HIV 
incidence. While approximately half of AGYW reported experiencing any IPV in the past year at 
baseline, we found no overall effect of IPV history on PrEP adherence in the full study 
population. In age-stratified analyses, among younger AGYW (<21 years), a history of IPV was 
found to hinder successful PrEP use. Adherence programs may be especially necessary to 
support younger AGYW who have experienced violence from a partner previously or are 
currently in a violent partnership given this group’s vulnerability to HIV and the potentially 
negative impact of IPV on achieving protection with PrEP. History of IPV among older AGYW 
(≥21 years) was associated with a greater likelihood of high PrEP adherence. Insight into the 
indirect effects of IPV in this age group may be helpful for efforts aimed at optimizing adherence 
among younger AGYW and other PrEP users. Lastly, alternative PrEP formulations may benefit 
AGYW who experience IPV and have trouble adhering to a daily oral PrEP regimen.  
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PRIMARY TABLES AND FIGURES 
 
Table 5.1. Baseline sample characteristics  
Participant characteristics, baseline 
N (% of total 
population) with 
characteristic 
N (% of those with 
characteristic) reporting 
any past-year IPV  
p* 
Site    
   Cape Town 134 (33%) 67 (51%)  
   Johannesburg 136 (33%) 64 (48%)  
   Harare  139 (34%) 68 (50%) .885 
Study arm    
   Enhanced adherence support 211 (52%) 110 (53%)  
   Standard adherence support 198 (48%) 89 (46%) .175 
Age group    
   <21 years 183 (45%) 87 (49%)  
   ≥21 years 226 (55%) 112 (50%) .781 
Completed secondary school or higher    
   Yes  248 (61%) 116 (48%)  
   No  161 (39%) 83 (52%) .416 
Worried about food in past year    
   Yes 301 (75%) 163 (55%)  
   No 98 (25%) 31 (32%) <.001 
Ever been pregnant    
   Yes 222 (54%) 120 (55%)  
   No 187 (46%) 79 (43%) .024 
Currently living with a partner    
   Yes 92 (22%) 56 (61%)  
   No 317 (78%) 143 (46%) .012 
Primary sex partner in past 3 months    
   Yes 343 (86%) 176 (52%)  
   No 55 (14%) 20 (36%) .031 
Any transactional sex in past 3 months    
   Yes 94 (25%) 57 (61%)  
   No  289 (75%) 133 (46.5%) .013 
Symptoms of depression    
   CES-D-10 score ≥12 142 (43%) 87 (62%)  
   CES-D-10 score <12 190 (57%) 81 (43%) <.001 
Perceived risk of acquiring HIV in next year     
   Moderate or great risk 66 (17%) 37 (57%)  
   No or small risk 319 (83%) 154 (49%) .238 
10 participants refused to answer food security question; 11 refused to answer main partner question; 26 refused 
transactional sex question; 77 refused at least one CES-D-10 item; and 24 refused risk perception question 
6 participants total coded as missing for having reported any past-year IPV 






Table 5.2. Exposure prevalence (N=409) 
 Baseline prevalence  
Type of violence Full sample, N (%) <21 years, N (%) ≥21 years, N (%) p* 
Physical IPV 81 (20%) 40 (22%) 41 (18%) .332 
Emotional IPV 148 (37%) 60 (33%) 88 (39%) .216 
Sexual IPV 35 (9%) 16 (9%) 19 (8%) .901 
Psychological IPV 75 (19%) 26 (15%) 49 (22%) .061 
Any IPV** 199 (49%) 87 (49%) 112 (50%) .781 
3 participants refused to answer physical IPV question, 5 refused emotional IPV question, 2 refused sexual IPV 
question, and 7 refused psychological IPV; refusals were coded as missing (6 total coded as missing for any IPV) 
*p-values for IPV-age relationship based on likelihood ratio chi-square tests  
**Any IPV coded as if reply yes to physical, emotional, sexual, or psychological then coded as “yes” to any; must 







Table 5.3. Effect of any IPV exposure on high PrEP adherence 
IPV Month TFV-DP ≥700 fmol/punch N Total N % PR (95% CI) aPR (95% CI)  p 
Any IPV 3 48 199 24.1 1.17 (0.81, 1.69) 1.21 (0.84, 1.76) .310 No IPV 3 42 204 20.6 1.00 (ref) 1.00 (ref) 
Any IPV 6 38 199 19.1 1.11 (0.73, 1.69) 1.09 (0.71, 1.67) .687 No IPV 6 35 204 17.2 1.00 (ref) 1.00 (ref) 
% = prevalence; PR = prevalence ratio; aPR = adjusted prevalence ratio; p = Wald chi-square p-value  
Prevalence ratio estimates and 95% CIs were calculated using log-binomial regression; p-values correspond to 






Table 5.4. Effect of any IPV (vs no IPV) exposure on high PrEP adherence by age 
 TFV-DP ≥700 fmol/punch at Month 3  TFV-DP ≥700 fmol/punch at Month 6 
Age group PR (95% CI) aPR (95% CI) p  PR (95% CI) aPR (95% CI) p 
<21 years 0.44 (0.22, 0.87) 0.43 (0.22, 0.86) .016  0.68 (0.31, 1.49) 0.66 (0.30, 1.46) .308 
≥21 years 2.11 (1.29, 3.47) 2.21 (1.34, 3.66) .002  1.38 (0.84, 2.27) 1.37 (0.82, 2.29) .230 
Age x IPV   <.001    .128 
PR = prevalence ratio; aPR = adjusted prevalence ratio; p = Wald chi-square p-value  
Prevalence ratio estimates and 95% CIs were calculated using log-binomial regression; p-values correspond to 
adjusted regression models; adjusted models controlled for country, education level, and food security; an alpha 









Figure 5.1. Distribution of IPV types among AGYW who reported any IPV (n=195) 
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SUPPLEMENTAL TABLES AND FIGURES 
 
Sensitivity analysis outcome coding 
 
 
Table 5.5. Prevalence of high PrEP adherence by outcome coding strategy 
TFV-DP ≥700 fmol/punch, DBS Month 3 (N=355) 
Month 6 
(N=346) 
Single imputation* (N=409) 90 (22.0%) 73 (17.9%) 
Monte Carlo sensitivity analysis (N=409) 97 (23.7%) 83 (20.3%) 
Complete-case analysis  90 (25.4%) 73 (21.1%) 





Monte Carlo sensitivity analysis 
 
 
Table 5.6. Effect of any IPV exposure on high PrEP adherence 
IPV Month TFV-DP ≥700 fmol/punch N Total N % PR (95% CI) aPR (95% CI)  p 
Any IPV 3 51 199 25.6 1.16 (0.82, 1.65) 1.17 (0.82, 1.67) .390 No IPV 3 45 204 22.1 1.00 (ref) 1.00 (ref) 
Any IPV 6 41 199 20.6 1.00 (0.68, 1.47) 0.97 (0.65, 1.44) .873 No IPV 6 42 204 20.6 1.00 (ref) 1.00 (ref) 
% = prevalence; PR = prevalence ratio; aPR = adjusted prevalence ratio; p = Wald chi-square p-value  
Prevalence ratio estimates and 95% CIs were calculated using log-binomial regression; p-values correspond to 





Monte Carlo sensitivity analysis 
 
 
Table 5.7. Effect of any IPV (vs no IPV) exposure on high PrEP adherence by age 
 TFV-DP ≥700 fmol/punch at Month 3  TFV-DP ≥700 fmol/punch at Month 6 
Age group PR (95% CI) aPR (95% CI) p  PR (95% CI) aPR (95% CI) p 
<21 years 0.49 (0.26, 0.91) 0.47 (0.25, 0.88) .017  0.62 (0.30, 1.28) 0.60 (0.29, 1.24) .168 
≥21 years 2.05 (1.27, 3.32) 2.08 (1.28, 3.39) .003  1.24 (0.79, 1.96) 1.22 (0.76, 1.96) .407 
Age x IPV   <.001    .105 
PR = prevalence ratio; aPR = adjusted prevalence ratio; p = Wald chi-square p-value  
Prevalence ratio estimates and 95% CIs were calculated using log-binomial regression; p-values correspond to 
adjusted regression models; adjusted models controlled for country, education level, and food security; an alpha 






Complete-case sensitivity analysis 
 
 
Table 5.8. Effect of any IPV exposure on high PrEP adherence 
IPV Month TFV-DP ≥700 fmol/punch N Total N % PR (95% CI) aPR (95% CI)  p 
Any IPV 3 48 180 26.7 1.09 (0.76, 1.56) 1.16 (0.81, 1.67) .416 No IPV 3 42 172 24.4 1.00 (ref) 1.00 (ref) 
Any IPV 6 38 171 22.2 1.09 (0.72, 1.63) 1.06 (0.70, 1.61) .782 No IPV 6 35 171 20.5 1.00 (ref) 1.00 (ref) 
% = prevalence; PR = prevalence ratio; aPR = adjusted prevalence ratio; p = Wald chi-square p-value  
Prevalence ratio estimates and 95% CIs were calculated using log-binomial regression; p-values correspond to 





Complete-case sensitivity analysis 
 
 
Table 5.9. Effect of any IPV (vs no IPV) exposure on high PrEP adherence by age 
 TFV-DP ≥700 fmol/punch at Month 3  TFV-DP ≥700 fmol/punch at Month 6 
Age group PR (95% CI) aPR (95% CI) p  PR (95% CI) aPR (95% CI) p 
<21 years 0.40 (0.20, 0.77) 0.39 (0.20, 0.77) .006  0.66 (0.30, 1.43) 0.64 (0.29, 1.39) .257 
≥21 years 2.03 (1.25, 3.29) 2.18 (1.34, 3.55) .002  1.35 (0.83, 2.19) 1.34 (0.81, 2.22) .252 
Age x IPV   <.001    .116 
PR = prevalence ratio; aPR = adjusted prevalence ratio; p = Wald chi-square p-value  
Prevalence ratio estimates and 95% CIs were calculated using log-binomial regression; p-values correspond to 
adjusted regression models; adjusted models controlled for country, education level, and food security; an alpha 








Table 5.10. Effect of different IPV exposure types on high PrEP adherence 
 TFV-DP ≥700 fmol/punch at Month 3  TFV-DP ≥700 fmol/punch at Month 6 
Type of IPV 
(IPV v no IPV) PR (95% CI) aPR (95% CI) p  PR (95% CI) aPR (95% CI) p 
Physical IPV 1.40 (0.93, 2.10) 1.45 (0.96, 2.19) .076  1.51 (0.96, 2.38) 1.57 (1.00, 2.48) .052 
Emotional IPV 1.29 (0.89, 1.86) 1.30 (0.90, 1.89) .158  1.28 (0.84, 1.94) 1.26 (0.82, 1.92) .292 
Sexual IPV 1.18 (0.65, 2.14) 1.17 (0.65, 2.11) .604  1.13 (0.56, 2.27) 0.95 (0.45, 2.02) .889 
Psychological IPV 1.18 (0.76, 1.84) 1.08 (0.69, 1.70) .726  0.94 (0.55, 1.63) 0.86 (0.49, 1.51) .603 
PR = prevalence ratio; aPR = adjusted prevalence ratio; p = Wald chi-square p-value  
Prevalence ratio estimates and 95% CIs were calculated using log-binomial regression; p-values correspond to 














N=10,000 (distribution of 10,000 randomly drawn probability values (p1) using the parameters: 
min=0.7, mode1=0.75, mode2=0.95, max=1.0) 
 
 
N=54 (distribution of random sample of p1; 54 = number missing month 3 outcome) 
 
 
N=63 (distribution of random sample of p1; 63 = number missing month 6 outcome) 
 











CHAPTER VI: CONCLUSIONS 
 
SUMMARY OF FINDINGS 
In AIM 1, we examined PrEP use disclosure and its effect on adherence among 200 
AGYW ages 16-25 initiating PrEP in South Africa. We estimated the relative prevalence of high 
adherence 3- and 6-months post-PrEP initiation among AGYW who disclosed their PrEP use 
compared to AGYW who did not, both overall and by age. Participants self-reported disclosure 
of their PrEP use during follow-up separately for parents, partners, and peers. High adherence 
was defined as ≥700 fmol/punch using intracellular tenofovir-diphosphate concentrations in 
dried blood spots. Participants had a median age of 19 years (IQR=17-21 years). Most AGYW 
disclosed to a parent (58%), partner (58%), or friend (81%) over 6 months of follow-up. Younger 
AGYW (≤18 years) were significantly more likely to disclose to a parent than older AGYW (>18 
years). We did not observe a strong effect of disclosure on adherence overall; however, among 
younger AGYW, those who disclosed to a parent were 6.8 times as likely to have high 
adherence at month 6 than those who did not (95% CI 1.02, 45.56). In contrast, among older 
AGYW, there was no significant effect of disclosure to a parent (aPR=0.69, 95% CI 0.17, 2.90). 
There was evidence (α=.15) of effect modification for disclosure to a parent by age at month 6 
(p=.062). At month 3, disclosure to a parent was not meaningfully associated with adherence, 
and there were no significant associations, either in the full study population or in the separate 
age strata, between high adherence and disclosure of PrEP use to a partner or a friend.  
In AIM 2, we examined the effect of IPV history on adherence to PrEP among AGYW 
ages 16-25 in South Africa and Zimbabwe. We estimated the relative prevalence of high PrEP 
adherence 3- and 6-months post-PrEP initiation among AGYW who reported at enrollment a 
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history of any IPV by a current or most recent partner in the past year compared to AGYW who 
did not, both overall and by age. IPV history included any self-reported physical, emotional, 
sexual, or psychological violence by a current or most recent partner occurring in the year prior 
to enrollment. High adherence was defined as ≥700 fmol/punch using intracellular tenofovir-
diphosphate concentrations in dried blood spots. A total of 409 PrEP-initiating AGYW were 
included in our analyses. Participants had a median age of 21 years (IQR=19-22 years). Half 
(49%) reported experiencing IPV in the past year, with emotional IPV being most common 
(37%). Overall, AGYW who reported IPV had a similar prevalence of high PrEP adherence as 
AGYW who reported no IPV at both months 3 and 6. However, there was evidence (α=.15) of 
effect modification by age at month 3 (p<.001): among AGYW <21 years, those who reported 
IPV were less than half as likely to have high PrEP adherence (aPR=0.43, 95% CI 0.22, 0.86); 
among AGYW ≥21 years, those who reported IPV were more than twice as likely to have high 
PrEP adherence (aPR=2.21, 95% CI 1.34, 3.66). There was also evidence of effect modification 
by age at month 6 (p=.128), and effect estimates within each age stratum were consistent in 









STRENGTHS AND LIMITATIONS 
The strengths and limitations of this dissertation will be considered in the context of the main 
threats to internal and external validity in epidemiologic research.  
1. In both studies, we note that our sample size was small and the proportion of 
participants with high adherence, particularly at month 6, was modest, limiting the 
precision of estimates and our ability to detect meaningful associations, as well as the 
generalizability of our findings to broader AGYW populations. PrEP research, however, 
has only recently expanded to include AGYW in this context, and the samples of AGYW 
initiating PrEP that were used for these analyses are among the first that include a 
biologic assessment of PrEP adherence, making this research extremely novel.  
2. In both studies, missing DBS data was common, requiring imputation of missing 
adherence values to facilitate analyses. While it is possible that missing outcome data 
biased our findings to some extent, our sensitivity analyses (complete-case, last 
observation carried forward, and Monte Carlo) indicated that our results were fairly 
insensitive to several different approaches to handling the missing data. 
3. For AIM 1, there is a potential for exposure misclassification using self-reported 
disclosure, which is subject to recall error. Further, since the 3P questionnaire assessed 
disclosure occurring since the previous visit at month 1, 2, 3, and 6, participants may 
have had a hard time recalling when disclosure events occurred and if they had reported 
an event previously. To limit the potential impact of this reporting bias, we estimated our 
exposure as disclosure to at least one individual within a specific social group within a 
certain time period, as opposed to measuring the total number of reported disclosures.   
4. For AIM 2, we were not able to estimate the effects of recent IPV exposure on PrEP 
adherence. While IPV in the past month was examined at months 3 and 6 in HPTN 082, 
we were not able to ascertain if IPV occurred during certain periods of follow-up (i.e., 
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months 1, 2, 4, and 5). Further, this assessment of IPV during follow-up overlapped with 
adherence measurement, limiting our ability to establish temporality between our 
outcome and exposure. Therefore, we were not able to accurately estimate recent IPV in 
this study. Additionally, IPV is a sensitive topic that may have been underreported by 
participants or subject to recall error, resulting in possible exposure misclassification.  
5. In both studies, there is likely unmeasured confounding and/or variation in exposure 
opportunity, which may dampen the validity of causal inferences. 
a. In AIM 1, the 3P survey did not ask participants who they were living with or if 
they had a living parent, potentially important covariate that may have impacted 
both disclosure/non-disclosure opportunity and PrEP adherence. Moreover, 
when examining disclosure to specific social groups, we were not able to control 
for variability in disclosure to other specific group types. Finally, the survey 
measured disclosure as a binary construct and did not capture level of disclosure 
(i.e., full or partial disclosure) or nuances in support received following disclosure.  
b. In AIM 2, we were not able to control for certain theorized covariates, including 
prior pregnancy, currently living with a partner, having a main partner in the last 
three months, and transactional sex in the last three months. Since our exposure 
(IPV) was assessed as in the past year at enrollment, we could not determine if 
these theorized covariates preceded IPV events. Therefore, we did not adjust for 
these variables in our analysis, which may have resulted in confounding bias. 
6. For both aims, our threshold for high adherence (700 fmol/punch) was based on 
research conducted among MSM and adults. Research aimed at identifying the most 




PUBLIC HEALTH IMPLICATIONS AND FUTURE DIRECTIONS 
Taken together, findings from AIM 1 and AIM 2 suggest that the impact of social and 
behavioral factors on PrEP adherence is likely to vary between AGYW of different ages. 
Adolescence is a period of rapid development which can lead to new sets of behaviors relating 
to health (51). Since most adolescents still live at home, parents can have a strong influence on 
adolescent motivations, decisions, and behaviors relating to health; adolescents often develop 
strong peer and partner relationships in their transition to young adulthood (52). The range of 
cognitive, psychological, and emotional processes experienced by AGYW in this unique 
developmental period are likely to modify the effects of social influences on trajectories towards 
health and wellbeing. Future research should consider the transitional nature of the adolescent 
developmental stage when designing social and behavioral interventions for AGYW. 
Findings from our quantitative investigation of PrEP use disclosure and adherence (AIM 
1) suggest that younger AGYW may benefit from parental support for effective PrEP use. More 
work is needed to understand parents’ potential role as PrEP allies, and to develop strategies 
for engaging parents in their child’s PrEP use. Further, adherence support programs for AGYW 
should find ways that peers and partners can help motivate effective PrEP use. Adherence 
programs should continue to support AGYW in considering the pros and cons of disclosure to 
specific social groups, provide AGYW with strategies to support discreet use, and help AGYW 
navigate non-disclosure to individuals and groups that may impede their effective PrEP use. 
Findings from AIM 1 inform other recommendations for future research. First, larger, 
open-label studies are needed to assess the effects we examined here, with the inclusion of 
additional relevant covariates and more nuanced measures of disclosure and social support. A 
larger sample would also provide more power to determine if the effects of disclosure vary by 
age, as we observed for disclosure to parents despite limited precision. Next, the effects of 
disclosure on adherence to daily oral PrEP should be compared to the effects of disclosure on 
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adherence to alternative dosing regimens (e.g., intermittent, on-demand) and formulations (e.g., 
topical, injectable, insertable) to determine if disclosure is more important for daily pill-taking 
compared to more discreet or longer-acting PrEP formulations. Last, more research is needed 
to understand barriers and facilitators to both disclosure and PrEP adherence. For example, 
qualitative research has identified stigma as a barrier to disclosure among AGYW and highlights 
the important role of multi-level PrEP programs (e.g., media campaigns, community outreach) in 
changing norms around sexuality and increasing community knowledge around PrEP (48).  
Findings from our quantitative investigation of IPV and PrEP adherence (AIM 2) suggest 
that adherence programs may be especially necessary to support younger AGYW who have 
experienced violence from a partner previously or are currently in a violent partnership given 
this group’s vulnerability to HIV and the potentially negative impact of IPV on achieving 
protection with PrEP. Further, insight into the indirect effects of IPV among older AGYW may be 
helpful for efforts aimed at optimizing adherence among younger AGYW and other PrEP users.  
Findings from AIM 2 inform several additional recommendations for future research. 
First, qualitative studies should explore the mechanisms by which IPV affects adherence to oral 
PrEP among both younger and older AGYW to better understand the differential effect of IPV 
we observed in this study. Then, quantitative research should explore variables on the causal 
pathway between IPV and PrEP adherence within age-specific strata to understand if there is a 
need for targeted adherence support for younger IPV victims, and which factors we can 
intervene upon to optimize adherence in this vulnerable group. Next, research should examine 
the effects of acute IPV exposure during PrEP use on adherence. Last, the effects of IPV on 
adherence to daily oral PrEP should be compared to the effects of IPV on effective use of 
alternative dosing regimens and modalities to determine if certain PrEP formulations are more 
appealing to AGYW with violent partners. Long-acting injectable cabotegravir, for example, 
offers protection from HIV without relying on adherence to a daily oral tablet, and may benefit 
AGYW who experience IPV and have trouble adhering to a daily oral PrEP regimen.  
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APPENDIX B: HPTN 082 BASELINE IPV QUESTIONNAIRE 
 
Now we will ask you some questions about your relationships with your partner, family, friends 
or other people in your neighbourhood. We know that relationships can have good and bad 
moments. Some questions may be difficult to answer and we would like to remind you that your 
answers will be kept CONFIDENTIAL. 
 
 
In the past year, has your current or most recent partner punched, slapped, kicked, bit you, or 
caused you any type of physical harm? 
 Yes 
 No 
 Prefer not to answer 
 
In the past year, has your current or most recent partner insulted, ignored or humiliated you, 
yelled at you, or made you feel ashamed or bad about yourself? 
 Yes 
 No 
 Prefer not to answer 
In the past year, has your current or most recent partner forced you to have sex or perform any 
sexual act, or touched you sexually in any way that you did not want? 
 Yes 
 No 
 Prefer not to answer 
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